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ABSTRACT

Autism is a lifelong neurodevelopmental disorder. The etiology of autism still
remains unclear due to the heterogeneous and complex nature of the disorder, however
synergistic actions between genetic components and environmental factors have been
suggested. Acetaminophen (APAP) is one of the most popular over-the-counter drugs
that possess antipyretic and analgesic effects. It is considered a relatively safe and
effective within therapeutic doses.

Recently, early exposure to APAP has been

suggested to be one of the underlying cause of autism. Children are often prescribed
APAP to lessen fever or irritability after vaccination during the first year, and APAP may
adversely affect the normal brain development.

In order to better understand the

association with APAP and autism, we used an inbred mouse strain BTBR T+tf/J
(BTBR). BTBR exhibits behavioral deficits that mimic the core behavioral deficits of
human autism. In the study, investigated 1) if BTBR mice showed differences in thiol
biochemistry and EAAT3 levels in brain compared with C57BL/6J (C57) mice, 2) if early
exposure to APAP induced behavioral changes worsening the autistic phenotypes of
BTBR in adolescence, and 3) if APAP exposure in neonatal mice induced possible
toxicity at various doses. As a result, we observed that BTBR mice have significantly
lower plasma sulfate levels and EAAT expression levels in the frontal cortex compared
to C57 mice. Surprisingly, neonatal therapeutic dose of APAP administration did not
induce behavioral changes in both C57 and BTBR in adolescence. However, we

v

showed that a supratheraputic dose of APAP significantly elevated levels of oxidative
stress marker in the brain. Overall, the results suggested that BTBR mice would be a
useful mouse model to investigate effects of various environmental factors that have
been associated with autism. In addition, early exposure to APAP at supratherapeutic
doses may negatively affect normal brain development.
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CHAPTER 1
INTRODUCTION

1.1

Autism Spectrum Disorders
Autism spectrum disorder (ASD) is a lifelong neurodevelopmental disorder that

can start early in development, even before the age of three. Autism spectrum disorders
include pervasive developmental disorder not otherwise specified (PDD-NOS),
Asperger syndrome and autism. Due to the highly heterogeneous nature in the types of
symptoms and degrees of the symptoms, ASD is referred to as a spectrum.
Nonetheless, there are some overlapping symptoms that are common in autistic
patients;

including abnormal social behavior,

impairment in

verbal/non-verbal

communication, and repetitive/stereotypic behaviors (Becker et al., 2013; Chen et al.,
2016; Klaiman et al., 2015). Multiple comorbidities, such as epilepsy, intellectual
disability, hyperactivity and gastrointestinal symptoms are also seen in autistic
individuals (Bitsika et al., 2015; Klaiman et al., 2015). Even though there is no definitive
cure for ASD, the symptoms can be treatable. However, these behavioral impairments
are still challenging and require attentive care and support.
A survey by the National Center for Health Statistics of Center for Disease
Control reported that 1 in 45 children have been diagnosed with ASD among the ages
of 3 to 17 in 2014 (Zablotsky et al., 2015). ASD is the most prevalent developmental
neurological disorder and the prevalence is estimated to increase with time, thus
1

drawing the attention of researchers, clinicians, and caregivers in the field. Currently,
various treatments and therapies are used to control co-morbidities and behavioral
impairments.

Special education systems,

medical treatments,

interventions are often needed for ASD patients.

and

behavioral

These treatments, which cost

approximately 60,000 US dollars for one autistic person without intellectual disabilities
and 85,000 to 107,000 US dollars for ASD patients with intellectual disabilities per year
(Amendah et al., 2011; Buescher et al., 2014). The economic cost in the U.S. for ASD is
estimated to be 268 billion US dollars in 2015 and it is anticipated to be increased to
461 billion US dollars by 2025 as ASD prevalence continues rise (Leigh et al., 2015).
Early diagnosis of ASD remains difficult not only because of the heterogeneity of
the disorder, but is also extensive to its unknown etiology. A large number of genes are
associated with ASD which further clouds the etiology of the disease. Some
main/common examples of ASD associated gene mutation include CNTNAP2, NLGN1,
NLGN3, NLGN4, NRXN1, SHANK1, SHANK2, SHANK4, PTEN, FMR1, and MECP2
(Buescher et al., 2014; Ergaz et al., 2016; Jiao et al., 2012; Kazdoba et al., 2016).
Although genetic factors have been suggested as the underlying cause of autism,
pathogenesis of autism is still not well defined as these genes do not account for many
of the ASD cases (Kazdoba et al., 2016). Furthermore, only about 10% of autism cases
have been associated with genetic factors (Chauhan et al., 2015; Deth et al., 2014).
Therefore, it is strongly suggested that environmental & genetic factors may contribute
together in autism pathogenesis (Koufaris et al., 2015). Research supports the
hypothesis that prolonged exposure to certain environmental factors, including diet, air
2

pollution, pesticides, drugs, infections and heavy metals (Koufaris et al., 2015) may
predispose genetically vulnerable individuals to develop autism.

1.2

Animal model of autism
ASD is characterized by distinct behavioral phenotypes which include impaired

social interaction, deficits in verbal/non-verbal communication and repetitive stereotypic
behaviors (Bitsika et al., 2015). Individuals are evaluated and diagnosed strictly based
on those behavioral impairments using the fifth edition of the Diagnostic and Statistical
Manual of Mental Disorders (DSM-5) (Zablotsky et al., 2015). Animal models of human
clinical conditions are useful to investigate underlying biological mechanisms of certain
diseases; this aids the development of diagnostic and therapeutic strategies. Several
murine models representing autism have been developed and investigated using gene
mutations associated with the disorder as well as environmental factors (Ergaz et al.,
2016). However, it is not easy to develop an animal model that accurately reflects what
is seen in ASD due to the given heterogeneity and complexity of autism. These animal
models often exhibit different types/severity of certain behaviors. In addition, ASD does
not have specific biomarkers that can be used to diagnose the disorder; thus, it is
harder to make an animal model that precisely mimics human clinical condition only
based on behavioral phenotypes. Therefore, developing a more suitable animal model
for ASD is imperative.
An established mouse model for ASD, the BTBR T+tf/J (BTBR) inbred mouse
strain,

is considered a strong animal model because it exhibits the three core

behavioral abnormalities seen in humans with autism (Blanchard et al., 2012;
3

MacPherson et al., 2008; Meyza et al., 2013; Sforazzini et al., 2016). The behavioral
phenotypes of the BTBR strain were first reported to be similar to human autistic
phenotypes in 2007 (Moy et al., 2007), and continue to be extensively investigated.
These mice consistently exhibit low sociability, abnormal communication, and
stereotypic repetitive behavior (Amodeo et al., 2012; Blanchard et al., 2012; Sforazzini
et al., 2016). Besides the behavioral phenotypes, complete corpus callosum agenesis
and reduced hippocampal commissure are key structural characteristics seen in the
brain of the BTBR strain (Bohlen et al., 2012; Ellegood et al., 2013; Meyza et al., 2013;
Sforazzini et al., 2016; Stephenson et al., 2011). The corpus callosum and hippocampal
commissure are white matter bundles composed of axons that interconnect the right
and left cerebral hemispheres. The distinct function of the corpus callosum remains
uncertain, but it has been reported that abnormalities within this region of brain are
associated with behavioral deficits that can be seen in autism, ADHD, and
schizophrenia (Dougherty et al., 2015; Erbetta et al., 2015; Goddard et al., 2015;
Hanaie et al., 2014; Hinkley et al., 2012; Wolff et al., 2015). Additionally, it has been
reported that corpus callosum integrity is associated with cognitive impairment that we
can see in the elderly population (Hinkley et al., 2012; MacPherson et al., 2008). While
recent evidence has shown that corpus callosum agenesis is not directly associated
with the cause of autism, it cannot be excluded as a possible contributor to ASD since
the behavioral deficits with callosal agenesis/partial absence overlap with some of
autistic behaviors; such as, intellectual disability, delayed development, and anxiety.
(Bloom et al., 2005; Chen et al., 2016; Fenlon et al., 2015; Hinkley et al., 2012;
MacPherson et al., 2008; Yang et al., 2009).
4

It has reported that BTBR mice showed reduced plasma sulfate levels compared
to C57BL/6J (C57) mice. Autistic patients and BTBR mice also show decreased
heparan sulfate, a highly sulfated glycosaminoglycan, in subventricular zone (SVZ) of
the lateral ventricles (LV) (Blanchard et al., 2012; Corley et al., 2012; Mercier et al.,
2012; Meyza et al., 2012; Pearson et al., 2013). It has demonstrated that mice with
reduced heparan sulfates synthesis developed autistic behavioral impairments (Irie et
al., 2012). Heparan sulfate synthesis within neurons is regulated by the ExT1 gene.
Using Ext1 knockout mice, they observed that these mice exhibited no differences in
their morphology in the brain, but developed autistic behavioral impairments that are
seen in human autistic patients. These deficits included social behavior, vocalization
and stereotyped/repetitive behaviors, as well as alterations in anxiety behaviors and
hypersensitivity to thermal stimuli; implying that heparan sulfate synthesis is essential in
normal brain development.
In addition, research focused on other mechanisms/pathways has supported the
impact of heparan sulfate on autism pathology. Gene deletion of sulfotransferases,
specifically Hs2st or Hs6st1, resulted in disruption in the normal corpus callosum
development at embryonic day 18.5, adding support to the fact that impaired heparan
sulfate physiology can affect functional connectivity in the brain resulting abnormal brain
development (Clegg et al., 2014; Conway et al., 2011). Taken all together, it is possible
that significantly reduced sulfate levels in the BTBR strain may cause disruption in
heparan sulfate formation contributing to callosal agenesis. Recently, a study using
proteomic analysis to compare cortical tissue of BTBR and C57 mice; they reported
differences in protein expressions that are associated with homeostatic processes,
5

neurotransmission, myelination and mitochondrial function (Wei et al., 2016).

Overall,

the BTBR strain has become a useful animal model to explore links between the
behavioral phenotypes and the underlying mechanisms of autism pathophysiology.
While focusing on characterizing behavioral phenotypes of the BTBR strain as a model
of autism. Additional biochemical and physiological characterizations in these animals
still need to be explored to understand idiopathic autism pathophysiology.

1.3

Detoxification of xenobiotics and sulfation
It has been suggested that sulfate insufficiency may contribute to autism in

certain populations due to the reduced capability for detoxification of various toxic
compounds. Sulfate converts toxic compounds to non-toxic sulfoconjugates by sulfation.
Sulfur exists as sulfate (SO4-) in animals. The level of sulfate is maintained by
dietary sulfur-containing protein intake, of which most are composed of amino acids,
methionine and cysteine (Bowling et al., 2013). In the liver, most drugs and xenobiotics
are metabolized through phase 2 detoxification mechanisms, glucuronidation and/or
sulfation.
Drugs are metabolized through liver enzymes as phase 1 detoxification.
Metabolites and remaining portions of the parent drug are further metabolized using
phase 2 detoxification mechanisms by forming conjugations. Glucuronidation is
catalyzed by a glucuronosyltransferase which moves the glucuronic acid of its substrate
Uridine 5'-diphospho-glucuronic acid (UDT-glucuronic acid) onto xenobiotics (Fujiwara
et al., 2016). Sulfation occurs via phenolsulfotransferases adding sulfate group to
foreign substances (Kern et al., 2013). In adults, glucuronidation is primarily responsible
6

for detoxification; but in pediatric population, sulfation is the major route for the
clearance of drugs (Arana et al., 2001). It has been suggested that autism patients have
lower sulfation capacity and increased sulfate excretion implying possible sulfate
deficiency in certain populations of autism patients (Hartzell et al., 2012). In addition, the
insufficient sulfation capability with phenolic amines has been reported, suggesting
abnormal neurotransmitter biotransformation, especially with catecholamines, leading to
neurotoxicity. Taken together there may be an important role of sulfur in the pediatric
population, and specifically those with ASD.
In the process of detoxification, sulfate is converted to 3’-phosphoadenosine-5’phosphosulfate (PAPS), the universal sulfur donor in animals. PAPS donates sulfuryl
groups to compounds catalyzed by phenolsulfotransferase, producing a sulfated
compound and 3’-phosphoadenosin-5’-phosphate (PAP) (Klaassen et al., 1997a;
Klaassen et al., 1997b). Acetaminophen (APAP), a popular antipyretic, that is often
used after early age vaccinations, needs to be sulfated by PAPS to be secreted via the
kidney (Klaassen et al., 1997a). In the pediatric population, inadequate sulfate levels
lead to greater amounts of APAP being metabolized by cytochrome P450 2E1 (CYP
2E1). This alternative route of metabolism generates more of the toxic metabolite, Nacetyl-p-benzoquinonimine (NAPQI). NAPQI overproduction is known to cause
glutathione (GSH) depletion. GSH is a tripeptide that is composed with cysteine,
glutamic acid and glycine, and is one of the essential cellular antioxidant, and also plays
an important role in detoxification of xenobiotics and cellular protection against
electrophilic compounds. NAPQI forms covalent bonds with GSH, lowering its
availability, and result in severe liver damage (A. Abdin, 2013). The ratio of APAP7

sulfate conjugates and APAP-glucuronide conjugates was significantly lower in severe
autism patients suggesting insufficient sulfation for detoxification (Alberti et al., 1999).
In detoxification, GSH forms covalent bonds with xenobiotics and nucleophiles
via glutathione-s-transferase (GST) forming mercapturic acids, making the compounds
inactive (Pocernich et al., 2012; Townsend et al., 2003). Furthermore, low levels of
plasma inorganic sulfate and GSH levels have been reported in autistic individuals
(Adams et al., 2011; Wood, 2014). Both sulfate and GSH are critical for detoxification
and lower levels are associated with increased in xenobiotic induced cellular toxicity and
oxidative stress (Hartzell et al., 2012). Several studies found that autistic individuals
have abnormal sulfate chemistry, insufficient thiol levels, and decreased GSH, which
make individuals more vulnerable to environmental toxins due to the imbalance in redox
state and reduced detoxification capacity (James et al., 2004; James et al., 2006; Kern
et al., 2013).

1.4

Acetaminophen
APAP is an analgesic and antipyretic agent that effectively relieves pain and

fever in all age groups (Ishida et al., 2007; Kis et al., 2005). It is also used for treating
the common cold, headaches, toothaches, body aches, and menstrual cramps. APAP
can serve as an effective antipyretic in infants and children as well (Shaheen et al.,
2010). In a human study, the half-life of APAP was prolonged in neonates and younger
children compared to adults, which can increase its possible accumulation in the plasma
(Arana et al., 2001); thereby making pediatric population more vulnerable to APAP
associated side effects. APAP is mainly metabolized in the liver and excreted via the
8

kidney by conjugating with glucuronic acid and sulfate (Fig. 1.1). In the liver, about 10 to
15% of APAP is metabolized by cytochrome P450 enzymes (mainly the CYP 2E1
isoform). This subsequently generates its toxic metabolite, NAPQI.

NAPQI is then

mercapturated by GSH and is excreted via the kidney. Excessive amounts of NAPQI
can deplete GSH, leading to disrupted redox homeostasis (Anderson, 2008; BlecharzKlin et al., 2014). In addition, NAPQI is a strong electrophile that can bind with
biomolecules such as DNA, proteins and lipids, and lead to cellular damage and
ultimately, liver failure with APAP overdose (Gum et al., 2013; Kalinec et al., 2014;
Nassini et al., 2010). Although less studied than hepatotoxicity, it has been shown that
APAP is able to cross the BBB where it can be metabolized by CYP 2E1, suggesting
potential neurotoxicity (Fischer et al., 1981). Studies have shown that 4AP, another
APAP metabolite formed in the liver, can cause renal failure without inducing severe
liver damage by acting in three different ways (Harmon et al., 2006; Mach et al., 2014;
McConkey et al., 2009). First, 4AP is converted to electrophilic compounds by CYP 2E1
in kidney (Newton et al., 1982). Second, production of GSH-4AP conjugate leading to
GSH depletion. Third, N-deacetylase catalyzes APAP conversion to 4AP and produces
free radicals. In the brain, 4AP is converted to N-arachidonoylphenolamine (AM404) by
conjugating with arachidonic acid. This reaction is catalyzed by fatty acid amide
hydrolase (FAAH). AM404 is known to inhibit reuptake of anandamide, an endogenous
cannabinoid, thereby exerting its analgesic effect (Becker et al., 2010; Hogestatt et al.,
2005; Schultz et al., 2008). It has been suggested that APAP alters the brain
endocannabinoid system during early development, resulting in behavioral changes
9

associated with developmental disorders such as ADHD and autism (Becker et al.,
2010; Schultz et al., 2008; Shaw, 2013).
In the US, about 79% of the population takes APAP regularly and about 35% of
women take APAP during pregnancy (Posadas et al., 2007). During the first year,
children are often prescribed APAP to lessen fever or irritability after vaccination. In
addition, epidemiological studies suggested that APAP administration during pregnancy
may result in ADHD-like behavior (Liew et al., 2014) and APAP administration after
vaccination may increase the risk of autism (Shaw, 2013). In fact, Posadas et al. (2010)
showed that APAP induces apoptosis of rat cortical neurons both in vitro and in vivo at
lower doses than that known to induce liver damage. Moreover, da Silva et al. (2012)
showed increased oxidative stress and disrupted mitochondrial function in mouse brain
after toxic dose of APAP administration, implying acute neurotoxicity. It has also
reported that brain amino acids levels were changed with chronic administration of
therapeutic doses of APAP, suggesting that it induces altered neurotransmission, which
may be involved in neurobehavioral changes (Blecharz-Klin et al., 2014). However, the
available research is inadequate to explain APAP-induced changes during brain
development that could lead to developmental disorders.

10

Figure 1.1 APAP metabolism. APAP is first metabolized in the liver by CYP450 2E1.
During this process, the toxic metabolite NAPQI is generated. Within the therapeutic
dose, NAPQI can conjugate with GSH and cysteine. However when overdosed, NAPQI
overproduction results in GSH depletion leading to tissue damages. APAP also pass
through phase 2 detoxification; glucuronication and sulfation. Some portion of the
remaining APAP can be deacetylate into 4AP.

11

1.5

Oxidative stress
Even though the brain is only 2% of the total body weight, it’s high oxygen

consumption (approximately 20%) can result in the production of excess free radical byproducts. Also, the brain has a high concentration of polyunsaturated fatty acid,
contains oxidizing metals such as Cu2+ and Fe2+, and has relatively low superoxide
dismutase, catalase, and glutathione peroxidase activity compared to other organs.
Thus, the brain is more prone to oxidative stress (Berk et al., 2008; Schmidt et al.,
2012).
Oxidative stress presents when the equilibrium of free radical formation and
removal is not balanced. Free radicals, such as reactive oxygen species (ROS) and
reactive nitrogen species (RNS), are generated during normal oxidative metabolism.
The inability to remove these free radicals, which can include superoxide anion,
hydrogen peroxide, hydroxyl radical, nitric oxide (NO) and peroxynitrite, can damage
biomolecules that are essential to normal physiological function (Oztop et al., 2012;
Raymond et al., 2014; Wilkins et al., 2013).
Increases in oxidative stress and reductions of antioxidant capacity in autism
have been extensively studied (Chauhan et al., 2015; Gu et al., 2013; James et al.,
2004). Oxidative stress, caused by the imbalance of redox states, can result in cellular
stress and cytotoxicity (Schmidt et al., 2012). Increased oxidative stress is strongly
associated with numerous neurological disorders including autism (Ehrhart et al., 2015;
Gaki et al., 2014; Kim et al., 2015; Kulak et al., 2012; Zhang et al., 2014) .
Aforementioned, GSH is important for protecting cells against oxidative stress
and detoxification. GSH maintains cellular reduction-oxidation balance by reducing free
12

radicals. Since GSH can scavenge free radicals both enzymatically and nonenzymatically, it is the primary cellular defense system to maintain redox homeostasis in
the brain. GSH reacts with free radicals via glutathione peroxidase (GPx), resulting in
the generation of glutathione disulfide (GSSG), the oxidized form of GSH. GSSG is then
converted back to two molecules of GSH via glutathione reductase (GR) utilizing
NADPH (nicotinamide adenine dinucleotide phosphate) as a cofactor; thus, balancing
cellular redox status. In addition to its antioxidant properties, GSH is also involved in
detoxification of xenobiotics and protection of cells against nucleophiles via glutathiones-transferase (GST). GSH forms covalent bonds with xenobiotics and nucleophiles,
inactivating these compounds (Pocernich et al., 2012; Townsend et al., 2003). As stated
above, GSH exists in cells as both a reduced (GSH) and oxidized (GSSG) form, and the
optimal GSH/GSSG ratio needs to be maintained for normal cellular function (Johnson
et al., 2012; Zhou et al., 2014). Abnormal GSH/GSSG indicates an imbalance in cellular
redox homeostasis. Cells depleted of GSH are more vulnerable to oxidative stress, and
it is well known that the disrupted GSH system and increased oxidative stress is
strongly associated with neurodegenerative diseases as well as neuropsychiatric
diseases such as anxiety, bipolar, schizophrenia and substance abuse (Aoyama et al.,
2012; Berk et al., 2008; Townsend et al., 2003). Additionally, low GSH/GSSG has been
reported in plasma (Gu et al., 2013; Heberling et al., 2015) and brains (Gu et al., 2013)
of autism patients.
GSH levels are maintained by intracellular de novo synthesis through two
coupled enzyme reactions (Fig. 1.2) (Johnson et al., 2012). First, cysteine and glutamic
acid form a di-peptide through γ-glutamylcysteine ligase (GCL) followed by glycine
13

addition to form GSH by GSH synthetase (GS). In this reaction, Cysteine is the ratelimiting component due to its relatively lower concentration compared to glutamic acid
and glycine (Aoyama et al., 2008; Le et al., 2011). Interestingly, in neurons, the majority
of cysteine has to be transported from the extracellular space through one of the
excitatory amino acid transporters (EAATs) (Cao et al., 2012; Crino et al., 2002).

14

Figure 1.2 GSH synthesis and function in neurons. GSH de novo synthesis occurs
in two enzymatic reactions. Cysteine is transported through EAAT3 in neurons and then
added onto glutamic acid forming γGC using GCL. The second step is the addition of
glycine via GS to form the final product, GSH. GSH is then used as antioxidant through
GPx converting H2O2 into H2O. Furthermore, GSH is used in detoxification when GST
forms mercapturic conjugates with various foreign substances.
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1.6

Excitatory amino acid transporter 3
GSH is a major antioxidant and the deficit in GSH homeostasis is linked to

etiology of many neurological disorders including schizophrenia, autism, Parkinson’s
disease and other neurodegenerative diseases (Aoyama et al., 2013; Berk et al., 2008;
Townsend et al., 2003). In the brain, GSH is mainly generated from astrocytes and then
transported into extracellular spaces to be used by other types of cells (Rae et al.,
2016). There are no known GSH transporters in neurons, therefore GSH is further
catabolized by ectoenzyme aminopeptidase to be broken apart into glutamylcysteine,
cysteine, glycine and/or glutamic acid (Baxter et al., 2016; Shih et al., 2003). Synthesis
mainly relies on cysteine availability, as cysteine is the rate-limiting component in the
GSH de novo synthesis. About 90% of the cysteine is supplied from extracellular space
through the excitatory amino acid transporter 3 (EAAT3) in neurons (Johnson et al.,
2012). EAAT3 may therefore have an essential role in neuroprotection against oxidative
stress
EAATs are Na+-dependent glutamate transporters. EAATs require transport of 3
Na+ and 1 H+ into the cells and 1 K+ out of the cells. There are five EAATs (EAAT 1-5)
for balancing extracellular glutamate levels in CNS. Among the five transporter families,
EAAT3 (also termed EAAC1 and Slc1a1, solute carrier family 1 member 1) is a neuronspecific transporter found throughout the nervous system and is localized in cell bodies
as well as processes. About 20% of EAAT3 transporters are expressed at the plasma
membrane in a resting state and it is increased by translocation upon stimulation due to
oxidative stress and excitotoxicity (Escartin et al., 2011). EAAT3 is involved in the
glutamate reuptake from extracellular space, which is used to produce γ-aminobutyric
16

acid (GABA) in GABAergic neurons in the cortex and hippocampus. This indicates
EAAT3 may have an important role in neurotransmission regulation (Guo et al., 2015;
Raiteri et al., 2015). EAAT3 is unique, compared to other EAATs in the family, due to
the ability to transport cysteine into neurons (Aoyama et al., 2008; Cao et al., 2012).
EAAT3 is known to mediate cysteine transport to supply cysteine for neuronal GSH
synthesis; therefore, participating in neuroprotection (Robert et al., 2014). EAAT3
knockout mice have decreased dopaminergic neurons, and n-acetylcysteine (NAC)
treatment restored the loss of dopaminergic neurons by increasing thiol content
(Escartin et al., 2011). EAAT3 knockout mice were also more vulnerable to oxidative
stress due to the GSH depletion by MPTP treatment, and NAC had protective effects
against MPTP induced oxidative stress by replenishing GSH (Aoyama et al., 2006). In
addition, it has demonstrated that NAC opposed the age dependent dopaminergic
neuron loss in substantia nigra pars compacta and significantly elevated activated
microglia as well as nitrotyrosine and nitrated α-synuclein in EAAT3 knockout mice
(Berman et al., 2011).
The EAAT3 expression can be fluctuated by various factors resulting in GSH
homeostasis. It has been shown that chronic postnatal stress causes decreased EAAT3
expression in the hippocampus and frontal cortex in adolescent rats (Odeon et al.,
2015), and chronic morphine exposure resulted in decreased EAAT3 expression in rat
hippocampal neurons (Guo et al., 2015). It has been demonstrated that proline rich
opioid peptides, derived from casein and gliadin, modulate cysteine uptake in human
neuroblastoma cells and colon carcinoma cells. Additionally, decreases in GSH/GSSG
and SAM/SAH were observed as well, resulting in oxidative stress due to decreased
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cysteine uptake through EAAT3 transporters (Trivedi et al., 2014). Furthermore,
genome wide promoter methylation was significantly increased by casein derived opioid
peptide similar to morphine treatment in accordance with cysteine uptake inhibition,
suggesting EAAT3 mediated cysteine uptake modulation and redox balance are
associated with epigenetic regulation of gene expression as well.
Neuregulin induced neuronal cobalamin production is regulated by intracellular
neuronal glutathione levels which depend on cysteine uptake through EAAT3 (Zhang et
al., 2015).

This implies that EAAT3 mediated cysteine uptake is important during

neurodevelopment modulating an essential neurohormone associated with normal
growth and differentiation. Also the study showed that wortmanin, the PI3K inhibitor,
opposed neuregulin 1 effects on maintaining glutathione balance and promoting
cysteine uptake. This suggests that EAAT3 mediated cysteine uptake and subsequent
glutathione production is possibly mediated by PI3K/AKT signaling cascade.
Besides the unique feature of EAAT3 as an exclusive neuronal cysteine
transport, EAAT3 is involved in glutamate uptake near GABAergic neurons utilizing
glutamate to generate GABA via enzyme for balanced neurotransmission (Crino et al.,
2002; Guo et al., 2015; Holmseth et al., 2012). It has been suggested that abnormal
GABA function may be associated with autism (Coghlan et al., 2012; Han et al., 2014;
Robertson et al., 2016). Lower GABA transmission is linked to multiple symptoms; such
as hyperkinesia, seizures, mental retardation, hyperactivity, which can be frequently
seen in autism as co-morbid symptoms (Hendren et al., 2009). It has been
demonstrated that cellular prion protein is associated with EAAT3 mediated glutamate
uptake as well as cysteine transport in cells (Guitart et al., 2015). In this study, cell
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viability with and without the EAAT3 inhibitor, L-aspartate-β-hydroxamate, was
compared under oxidative stress conditions as well as glutamate excitotoxicity. As a
result, EAAT3 inhibition increased cell death suggesting EAAT3 plays a role in
protecting neurons by regulating glutamate excitotoxicity and oxidative stress. Sodium
dependent cysteine uptake was increased when prion protein was presented under an
oxidative stress environment, but did not increase cysteine transport under normal
conditions. This suggests EAAT3 and prion protein interplay is essential when cells are
under oxidative stress.
EAAT3 activity is regulated by nuclear factor erythroid 2-related factor 2 (Nrf2)
(Escartin et al., 2011). The Nrf2/ARE (antioxidant response element) complex is
involved in cell survival in response to oxidative stress by regulation of gene expression
encoding antioxidant proteins (Steele et al., 2013), which are involved in various phase
2 detoxification genes such as GCL, GPx and GST to balance redox homeostasis
(Harvey et al., 2009; Maes et al., 2012; Mitsuishi et al., 2012; Wang et al., 2013);
therefore, addressing the importance of EAAT3 in neurons against oxidative stress
induced neurotoxicity by regulating glutathione redox homeostasis.

1.7

Objectives
Taken together, the objective was to determine if the commonly used ASD

mouse model, BTBR, would be more vulnerable to environmental factors due to the
diminished detoxification and antioxidant capacity compared to C57. Our hypothesis
was that the BTBR strain has lower plasma sulfate, brain EAAT3 expression and GSH
levels, thus making the strain more prone to oxidative stress induced by neonatal
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exposure to APAP. In chapter 2, BTBR strain was compared to C57 in terms of plasma
sulfate, brain EAAT3 expression and GSH levels. In chapter 3, we evaluated if the early
exposure to APAP exacerbated autistic symptoms in BTBR and C57 strains. In chapter
4, we determined the toxic effects of early exposure to APAP in both BTBR and C57
strains.
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CHAPTER 2
Altered EAAT3 Expression and Plasma Sulfate Levels in the BTBR Mouse Model
of Autism

2.1

Introduction
Autism is a neurodevelopmental disorder that is characterized by behavioral

deficits

including

abnormal

social

behavior,

impairment

in

verbal/non-verbal

communication, and repetitive/stereotypic behaviors (Becker et al., 2013; Chen et al.,
2016; Klaiman et al., 2015). Multiple comorbidities, such as epilepsy, hyperactivity, and
gastrointestinal symptoms are seen in autistic individuals, and symptoms are highly
heterogeneous (Bitsika et al., 2015; Klaiman et al., 2015). While genetic factors have
been suggested as the underlying causes of autism, pathogenesis of autism is not well
defined and a large number of genes seem to be involved. However, only about 10% of
autism cases have been associated with genetic factors (Chauhan et al., 2015; Deth et
al., 2014); therefore, it is strongly suggested that in addition to genetic factors,
environmental factors also contribute to autism pathogenesis.
Animal models are useful tools to investigate underlying biological mechanisms
of diseases. The inbred murine strain, BTBR T+tf/J (BTBR), is considered a strong
animal model of autism because it exhibits three core behavioral abnormalities seen in
humans with autism; a disease that is diagnosed purely by behavioral deficits
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(Blanchard et al., 2012; MacPherson et al., 2008; Meyza et al., 2013; Sforazzini et al.,
2016). Behavioral characteristics of BTBR mice have been extensively investigated and
these mice consistently exhibit impaired social interaction, abnormal vocalization, and
stereotypic repetitive behavior (Blanchard et al., 2012; Corley et al., 2012). This strain
also exhibits similar neuroanatomical hallmarks of autism, such as agenesis of the
corpus callosum and reduced hippocampal commissure (Blanchard et al., 2012; Meyza
et al., 2012; Meyza et al., 2013). Moreover, evidence has been reported for impaired
sulfation, with significantly lower plasma sulfate levels (Corley et al., 2012) and
decreased brain levels of heparan sulfate (Blanchard et al., 2012; Meyza et al., 2012) in
comparison to the inbred C57 mouse strain, a commonly used comparison strain to the
BTBR. These findings are consistent with reports of heparan sulfate deficiency in
autistic postmortem brain tissue (Pearson et al., 2013) as well as abnormal sulfation
capacity (Waring et al., 1997) and decreased sulfate conjugation of acetaminophen
found in autistic children (Alberti et al., 1999). Thus, the BTBR strain is a valid animal
model to explore links between the behavioral phenotypes and the possible underlying
causes of autism.
In the liver, xenobiotics are metabolized through glucuronidation and/or sulfation,
both phase 2 detoxification mechanisms. While glucuronidation is more responsible for
detoxification in adults, sulfation is the major metabolic pathway in newborns (Arana et
al., 2001), suggesting an important role of sulfur in the pediatric population. The level of
sulfate is maintained by dietary sulfur-containing protein composed of amino acids
methionine and cysteine (Bowling et al., 2013). Low levels of plasma inorganic sulfate
and glutathione (GSH) have been reported in autistic individuals (Adams et al., 2011;
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Wood, 2014).

In fact, lower levels of both sulfate and GSH are associated with

increased xenobiotic induced cellular toxicity and oxidative stress (Hartzell et al., 2012).
GSH is the main tri-peptide thiol that protects cells against oxidative stress
(Schmidt et al., 2012). GSH reacts with free radicals via glutathione peroxidase (GPx),
resulting in the generation of glutathione disulfide (GSSG), the oxidized form of GSH.
GSSG is then converted back to GSH via glutathione reductase (GR), which uses a
NADPH (Nicotinamide adenine dinucleotide phosphate) coupled enzymatic reaction
(Dickinson et al., 2002). The ratio of GSH to GSSG indicates cellular redox states and
optimal ratio needs to be maintained for normal cellular function (Johnson et al., 2012;
Zhou et al., 2014). In addition, GSH is also involved in detoxification of xenobiotics and
protection of cells against nucleophiles via glutathione-s-transferase, GST forming
covalent bonds between GSH and xenobiotics or nucleophiles, rendering them inert and
allowing for eliminiation from the body (Pocernich et al., 2012; Townsend et al., 2003).
GSH levels are maintained by intracellular de novo synthesis through two coupled
enzyme reactions (Johnson et al., 2012). First, Cysteine (Cys) and glutamic acid form a
di-peptide through γ-glutamylcysteine ligase (GCL) followed by glycine addition by GSH
synthetase (GS) to form GSH. In this reaction, Cys is the rate-limiting component due to
its relatively lower systemic concentration compared to glutamic acid and glycine
(Aoyama et al., 2008; Le et al., 2011). In neurons, the majority of Cys has to be
transported from the extracellular space through one of the excitatory amino acid
transporters (EAATs), EAAT3 (Cao et al., 2012; Crino et al., 2002).
Unlike other EAATs, EAAT3 (also termed EAAC1 and Slc1a1- solute carrier
family 1 member 1) is thought to be mainly involved in cysteine uptake rather than
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glutamate clearance from the extracellular space (Aoyama et al., 2008; Cao et al.,
2012). At a resting state, about 20% of EAAT3 is expressed at the plasma membrane,
but is increased by translocation from intracellular in response to oxidative stress and
excitotoxicity (Escartin et al., 2011). It has been reported that chronic postnatal stress
decreased EAAT3 expression in the hippocampus and frontal cortex of adolescent rats
(Odeon et al., 2015) and could have significant neurodevelopmental consequences.
Odeon et al. (2015) showed that EAAT3 knockout mice were more vulnerable to
oxidative stress and had greater loss of dopaminergic neurons following treatment with
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). NAC (N-acetyl-cysteine), a wellknown antioxidant that does not require EAAT3 to get into the cell (Aruoma et al., 1989;
das Neves Duarte et al., 2012), provided protection against MPTP induced oxidative
stress. NAC also restored the loss of dopaminergic neurons by increasing thiol content
(Escartin et al., 2011) and by replenishing GSH stores (Aoyama et al., 2006) in EAAT3
knockout mice. These findings suggest that EAAT3 plays a pivotal role in maintaining
intracellular GSH levels by supplying Cys for GSH de novo synthesis in neurons.
Although numerous genes have been implicated in association with autism, the
etiology of this disease is still unclear. Many researchers have proposed that prolonged
exposure to certain environmental toxins, such as thalidomide, lead, and mercury, may
predispose genetically vulnerable individuals with reduced detoxification capability to
autism (Chauhan et al., 2015; Dufault et al., 2009; Kern et al., 2013; Stringari et al.,
2006).
Cells depleted of GSH are more vulnerable to oxidative stress, and it is well
known that a disrupted GSH system is strongly associated with neurodegenerative
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diseases, as well as neuropsychiatric disorders, such as anxiety, bipolar disorder,
schizophrenia and substance abuse (Aoyama et al., 2012; Berk et al., 2008; Pearson et
al., 2013). Indeed, low GSH/GSSG levels have been reported in the plasma (Gu et al.,
2013; Heberling et al., 2015) and brains (Chauhan et al., 2012; Gu et al., 2013; Rose et
al., 2012) of autism patients.
We hypothesize that some autistic children may have been more vulnerable
neurodevelopmentally due to coincident reductions in both plasma sulfate and brain
EAAT3 transporter levels, which increased environmental toxin induced oxidative stress
and neurotoxicity. To test this hypothesis, the present study sought to investigate
whether the BTBR mouse model of autism exhibits differences in thiol biochemistry and
EAAT3 expression in brain when compared with C57 mice.

2.2

Materials and Methods

2.2.1 Animal housing and maintenance
All procedures herein were in accordance with the animal protocol approved by
the University of South Florida (USF) Institutional Animal Care and Use Committee
(IACUC). 6 week old male BTBR T+tf/J and C57BL/6J mice were purchased from the
Jackson Laboratory and mice were subjected to experiment at 7 weeks of age. Upon
arrival, four littermates were housed per cage and mice were maintained in controlled
conditions at 22 ± 2 ˚C on 12h light/dark cycle. Mice were acclimated for 7 days prior to
the start of the experiment. Mice were provided with standard rodent chow and water ad
libitum.
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2.2.2 Tissue preparation
Mice were anesthetized with CO2 and then blood samples were collected by
cardiac puncture into EDTA containing tubes. Plasma was isolated by centrifugation at
1500g for 30 min. After centrifugation, the upper plasma layer was carefully collected
into new 1.5mL conical vials and stored at -20 °C for further biochemical analysis. Mice
were then perfused transcardially with phosphate buffered saline (PBS), and brains
were removed. The brains were divided sagittally into equal hemispheres. One
hemisphere

of

each

brain

was

fixed

in

4%

paraformaldehyde

(PFA)

for

immunohistochemistry, and the other hemisphere of the brain was dissected to isolate
the frontal cortex, and then rapidly frozen in liquid nitrogen before storage at -80 °C for
Western blotting.

2.2.3 Plasma inorganic sulfate analysis
Inorganic sulfate levels in plasma were analyzed using QuantiChromTM Sulfate
Assay Kit (BioAssay) according to manufacturer’s instruction. First, plasma samples
were deproteinated with the TCA reagent by centrifugation and the supernatant was
transferred to a 96 well plate. Next, the working reagent was mixed with the collected
supernatant and absorbance was measured using a multimode plate reader (EnSpire®,
PerkinElmer) set to read at a wavelength of 540nm. This method measures inorganic
sulfate quantitatively by measuring the turbidity due to insoluble barium sulfate
formation in polyethylene glycol.
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2.2.4 GSH/GSSG analysis in the plasma and the brain
GSH levels were measured by o-phthalaldehyde (OPA) derivatization using
Glutathione Fluorometric Assay Kit (Biovision). GSSG levels were measured by
reducing GSSG to GSH after quenching existing GSH activity. According to
manufacturer’s instruction, plasma and brain homogenates were obtained and
deproteinated with 6N perchloric acid. Samples were then neutralized with 6N
potassium hydroxide prior to OPA addition for reaction. Fluorescent intensity was
measure at Ex/Em = 340/420 nm.

2.2.5 mRNA expression of Slc1a1, Gclc, Gclm and Gsr in frontal cortex
Real time qPCR was carried out to measure Slc1a1, Gclc, Gclm and Gsr in
frontal cortices of BTBR and C57 mice (n=3). Tissue was collected and treated with
RNAlater® RNA stabilization reagent (Qiagen). Total RNA extraction was performed by
RNeasy® Mini kits (Qiagen) according to manufacturer’s instructions. RNA quantity and
quality were assessed by the 260/280 nm absorbance ratio using Nanodrop™. 0.6 μg of
total RNA was used to synthesize cDNA using RT 2 First Strand Kit (Qiagen). Primer
sequences were obtained from Harvard University’s public database, PrimerBank.
Primers used for amplification of gene transcripts were as follows: Slc1a1 Fwd 5’-TCG
TFF TTC GAG GAC ACA GT-3’; Slc1a1 Rev 5’-CGA TCA GCG GCA AAA TGA CC-3’;
Gclc Fwd 5’- GGG GTG ACG AGG TGG AGT A-3’; Gclc Rev 5’- GTT GGG GTT TGT
CCT CTC CC-3’; Gclm Fwd 5’- AGG AGC TTC GGG ACT GTA TCC-3’; Gclm Rev 5’GGG ACA TGG TGC ATT CCA AAA-3’; Gsr Fwd 5’- GAC ACC TCT TCC TTC GAC
TAC C-3’; Gsr Rev 5’- GGG ACA TGG TGC ATT CCA AAA-3’. The mouse Gapdh
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primer was obtained from IDT PrimeTime® (Ref Seq # NM_008084(1)). A master mix
solution was prepared with 2.5 μL of PowerUp™ SYBR Green Master Mix, 0.15 μL of
primers (stock conc. 10 μM) and 1.2 μL H2O per sample. 1 μL of cDNA and 4 μL of the
master mix were added to each well in a 384 well plate (Thermo Fisher). All samples
were run in triplicate by the BioRad CFX384™ Real-Time PCR Detection system. The
data were analyzed using ΔCt and ΔΔCt calculations and expressions of all genes were
normalized to mouse Gapdh.

2.2.6 EAAT3 protein expression in brain
EAAT3 protein expression levels were obtained via immunohistochemistry and
Western blotting. For immunohistochemistry, brain tissues were fixed with 4% PFA
overnight and immersed in a 30% sucrose solution for 2 days for dehydration. Tissues
were then cryo-sectioned, resulting in 30-μm sections, with five sections per animal
selected for immunostaining. Tissue sections were blocked with 4% normal goat serum
and incubated with EAAT3 (Sigma, 1:500, Rabbit), NeuN (Abcam, 1:1000, Mouse) at 4
˚C overnight. Tissue sections were incubated with Alexa Fluor® 488 conjugated goat
anti-rabbit and Alexa Fluor® 594 conjugated goat anti-mouse secondary antibodies.
Stained sections were mounted with DAPI hardset mounting media (S1400,
VECTASHIELD). Fluorescence images were obtained at 20X magnification using a
Zeiss (MRc) microscope. Cells expressing green fluorescence were counted as number
of neurons, and cells expressing red puncta with green fluorescence were identified as
EAAT3 expressing neuronal cells. Three fields were randomly chosen in frontal cortex
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of each tissue section and the ratio of EAAT3 positive neurons to total neurons was
calculated by an individual blinded to groups.
For Western blotting, the frontal cortex was dissected and snap frozen in liquid
nitrogen. Tissues were homogenized in lysis buffer (Sigma), and supernatant was
subjected to subcellular fractionation to obtain cytosolic and membrane by using
subcellular fractionation kit (Pierce) according to manufacturer’s instructions. 30 μg of
protein were loaded onto 10% SDS-PAGE gel and transferred onto nitrocellulose
membrane. Membranes were then blocked with 5% non-fat dry milk and incubated with
rabbit anti-EAAT3 antibody diluted with blocking buffer at 4 ˚C overnight. GAPDH and βactin were used for loading controls. After washing with 0.1% TBST, membranes were
incubated with secondary antibodies for 1 hr and visualized with Odyssey® Infrared
Imaging system. Band intensities were normalized to the protein concentration
calculated by BCA assay.

2.2.7 Statistical Analysis
All data are presented in mean and standard error of mean (SEM). Statistical
analysis was carried out using T-test and using Graphpad version 5.0.

2.3

Results

2.3.1 Plasma sulfate levels
To measure the differences in plasma inorganic sulfate levels, plasma samples
were collected from BTBR and C57 mice (n = 4). Sulfate levels were measured (Fig.
2.1) by turbidimetric assay. As a result, the BTBR mice were found to have significantly
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lower plasma sulfate levels (T-test, *p < 0.05) compared to C57 mice. This finding is in
agreement with the findings from Corley et al. (Corley et al., 2012)

that has also

demonstrated the BTBR mouse strain has reduced plasma sulfate levels.

2.3.2 GSH/GSSG levels
GSH and GSSG levels were measured in BTBR and C57 mice (n = 4) in plasma
and frontal cortex homogenates (Fig. 2.2). GSH and GSSG levels were not significantly
different between mouse strains in the frontal cortex. However, plasma GSSG levels
were significantly higher in BTBR compared to C57 mice (T-test, *p < 0.05), but no
significant differences were noted in GSH levels or GSH/GSSG ratios.
Furthermore, we measured mRNA expression levels of Gclc (gene encodes GCL
catalytic unit), Gclm (gene encodes GCL modifier) and Gsr (gene encodes GR) in
frontal cortices of BTBR and C57 mice. While mRNA expression levels of Gclm were
lower in BTBR than C57 mice (T-test, *p < 0.05), Gclc levels were similar in both mouse
strains (Fig. 2.3). GCL, a heterodimer that has catalytic unit and modifier unit, is also the
enzyme that synthesizes Cys and glutamic acid as the rate limiting step of GSH
biosynthesis (Fig. 1.1). While enzymatic activity of GCL is provided from Gclc, Gclm
increases the efficiency of GCL enzymatic activity (Cole et al., 2011; Yang et al., 2002).
Although we did not see significant changes in GSH levels in the brain, this lack of
support for efficient GSH production system may lead BTBR mice to be prone to a
greater degree of oxidative stress compared to C57 upon xenobiotics/oxidative
stressors.
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Gsr mRNA expression levels in BTBR mice were lower than those in C57 mice
(Fig. 2.3). Such decreased Gsr mRNA expression may also be associated with reduced
antioxidant capacity upon exposure to oxidants by accumulating GSSG as GR is the
NAD(P)H-dependent enzyme that reduces GSSG to GSH (Fig. 1.1). Although we did
not see differences in brain GSH and GSSG levels between two strains, our data
suggests the possible dysregulation in GSH recycling system in BTBR mice.
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Figure 2.1 Reduced levels of free sulfate in the plasma of BTBR versus C57 mice.
Plasma free sulfate levels were measured using turbidometric method from BTBR and
C57 mice. Interestingly, BTBR mice exhibited significantly lower plasma sulfate levels
(T-test, *p < 0.05) suggesting that BTBR may be vulnerable to drugs and xenobiotic
induced toxicity that require sulfation for detoxification.
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Figure 2.2 GSH/GSSG levels in BTBR and C57 mice. BTBR and C57 showed similar
levels of GSH and GSH/GSSG ratios in plasma. BTBR showed significantly increased
GSSG levels in the brain (T-test, *p < 0.05), but GSH levels were similar in both strains.
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Figure 2.3 Differences in mRNA expression levels of GSH related enzymes in
BTBR and C57 mice. RT-qPCR analysis of relative mRNA expressions of Gclc, Gclm,
and Gsr from frontal cortices of BTBR and C57 mice. Gclc levels were similar, but
BTBR showed significant decreases in Gclm and Gsr compared to C57 (T-test, *p <
0.05).

34

2.3.3 EAAT3 expression in Frontal cortex
The frontal cortex was dissected from a sagittally divided brain from each animal
(n = 4 per strain) (Fig. 2.4). Brain homogenates were fractionated into membrane and
cytosol, and Western blotting for EAAT3 was performed. Bands were normalized to
GAPDH for cytosolic fraction and to β-actin for membrane fraction. BTBR mice exhibited
significantly reduced EAAT3 expression in the frontal cortex when compared to the C57
strain, both in cytosolic (T-test, ***p < 0.001), and membrane (T-test, *p < 0.05)
fractions. After fluorescence immunostaining of EAAT3 (red, puncta) and NeuN (green)
(Fig. 2.5A), double labeling of EAAT3 and NeuN showed that the EAAT3 positive cells
were of neuronal lineage (scale bar = 50 μm; magnification = 20X). The BTBR strain
additionally exhibited reduced EAAT3/NeuN staining (arrowheads) compared to the C57
strain mice. The number of neurons expressing EAAT3 (Fig. 2.5B) were compared
between BTBR and C57 from all layers in the frontal cortex and displayed as the ratio of
EAAT3

expressing

neurons

over

NeuN

positive

neurons.

Representative

immunostained images from three different brain sections per animal were counted (n =
4), and revealed that BTBR showed a significantly lower number of neurons expressing
EAAT3 compared to C57 mice (T-test, ***p < 0.001).
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Figure 2.4 Differences in EAAT3 expression levels in BTBR and C57 mice. BTBR
and C57 mice showed different levels of EAAT3 expression in frontal cortices. EAAT3
expression was significantly decreased in BTBR mice both in cytosolic (T-test, ***p <
0.001) (A), and membrane fractions (T-test, *p < 0.05) (B); suggesting impaired cysteine
transport in neurons which may lead to BTBR mice being more vulnerable to drugs,
xenobiotics and/or subsequent oxidative stress.
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***

Figure 2.5 Differences in EAAT3 expression in the frontal cortices of BTBR and
C57 mice. Fluorescence immunostaining of EAAT3 (red, puncta) and NeuN (green) in
frontal cortex (A). Double labeling of EAAT3 and NeuN shows that EAAT3 positive cells
are also NeuN positive. BTBR mice show fewer EAAT3/NeuN positive cells compared
to C57 mice indicating lower cysteine availability in neurons in BTBR, suggesting lower
GSH biosynthesis (scale bar = 50 μm; magnification = 20X). The number of neurons
expressing EAAT3 (B) were compared between BTBR and C57 mice from all layers in
frontal cortices in ratios of EAAT3 expressing neurons to NeuN positive neurons. Three
images from three different brain sections per animal were used for counting (n = 4).
BTBR mice showed significantly fewer neurons expressing EAAT3 compared to C57
mice (T-test, ***p < 0.001)
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Using genetic databases (Yates et al., 2016) for SNP (Single nucleotide
polymorphism) analysis to investigate the reduced expression of EAAT3 seen in the
BTBR mouse strain, we detected

two polymorphisms in the open reading frame

upstream of the coding region (5’) of the mRNA when compared to the C57 strain (Fig.
2.6). SNPs were identified in the BTBR mouse strain in chromosome sequence
19:28835072-28835172. (5’) UTR variants are located at positions 19:28835122 and
19:28835127 and are identified as rs247522204 and rs216783576, respectively.
Contrary to the observed reduction in EAAT3 expression in the frontal cortex of
BTBR mice, mRNA concentrations remained unchanged as revealed by RT-qPCR
analysis demonstrating no significant fluctuations between the BTBR and C57 mice
(Fig. 2.7).
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www.Ensembl.org. Accessed 16 April 2016).

segment and identification of G/C base pairs within the sequence (Data exported from Ensembl.

rs247522204 and rs216783576, respectively. Data additionally provide GC content (% GC) within the gene

are identified in the blue boxes entitling “K” and “Y” and are labelled within the Ensemble database as

sequence 19:28835072-28835172 in the C1 band area. SNPs in the 5’ region of Slc1a1 (gene symbol of EAAT3)

the row titled “Variant – Sequence variants,” and are shown in comparison to the C57 mouse strain chromosome

Figure 2.6 SNP data of EAAT3 (Slc1a1) in the BTBR mouse strain. SNPs in the BTBR strain are located in

mRNA expression levels

Slc1a1
2.5
2.0
1.5
1.0
0.5
0.0
C57

BTBR

Figure 2.7. Differences in mRNA expression levels of EAAT3 in BTBR and C57
mice. RT-qPCR analyses of relative mRNA expression in Slc1a1 were assessed in
frontal cortex of BTBR and C57 (n = 4). Slc1a1 mRNA expression levels were similar in
BTBR and C57.
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2.4

Discussion
In the present study, BTBR mice were found to have significantly lower plasma

sulfate levels (Fig. 2.2), replicating a previous report using this animal model of autism
(Corley et al., 2012). This biochemical characteristic should make BTBR mice useful for
investigating the abnormal sulfation capacity (Waring et al., 1997) and decreased
sulfate conjugation of acetaminophen (Alberti et al., 1999) found in autistic children as
well as heparan sulfate deficiency in autistic postmortem brain tissue (Pearson et al.,
2013). We also found significantly higher GSSG in BTBR mice (Fig. 2.3) suggesting
higher levels of oxidative stress under basal condition. Taken together these findings
further support the view that the BTBR strain is a suitable model to investigate the
potential contribution of early exposure to environmental insults when sulfation is
primarily used for detoxification.
While we also found significantly decreased EAAT3 protein expression in the
frontal cortex of BTBR (Fig. 2.5 and 2.6), brain GSH, GSSG and the ratio of GSH/GSSG
were not significantly different between the two mouse strains. These findings are
inconsistent with others who have reported a close association between EAAT3
mediated cysteine uptake and GSH homeostasis in the brain (Berman et al., 2011;
Guitart et al., 2015; Trivedi et al., 2014; Zhang et al., 2016). However, we think there at
least three possible explanations are for these discrepancies. The first may be due to
the region of the brain we chose to investigate. While it is well-established that there are
anatomical abnormalities in several regions of autism brain, including frontal cortex,
hippocampus, amygdala and cerebellum (Amaral et al., 2008; Carper et al., 2005; Torun
et al., 2015), we examined the frontal cortex in since this area is greatly involved in
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social, language and executive functions affecting relevant behavioral phenotypes of
autism observed in this BTBR strain (Ellegood et al., 2013). However, it is possible that
frontal cortex GSH homeostasis is less dependent on optimal EAAT3 function than
other brain areas with greater sensitivity to oxidative stress, such as the hippocampus,
which has been demonstrated in EAAT3 knockout mice (Aoyama et al., 2006; Cao et
al., 2012). Thus, it will be important to investigate EAAT3 transporter levels and GSH
redox balance in other regions of brain that are relevant to autism in future studies.
Second, because basal GSH levels in neurons are lower than those in astrocytes,
microglia, and oligodendorocytes (Dringen et al., 1999; Hirrlinger et al., 2002), glial
sources of GSH in the frontal cortex homogenates may have masked any neuronal
GSH deficit associated with reduced EAAT3 expression. Third, compensatory
upregulation of other known cysteine uptake systems in neurons, such as the neutral
amino-acid transporter system (ASCT1) (Shafqat et al., 1993; Yamamoto et al., 2003),
may help maintain GSH homeostasis when EAAT3 mediated cysteine transport is
inadequate. This interpretation is consistent with those of (Li et al., 2011) who reported
that 8-week old EAAT3 knockout mice exhibited no significant reductions in cortical
GSH levels either before or after receiving middle cerebral artery occlusion despite
having larger brain infarct volumes and worse neurologic deficits that did wild-type
controls.
Perhaps more important than GSH levels under basal conditions, we also
observed a significant decrease in mRNA expression levels of Gclm and Gsr in the
frontal cortex of BTBR mice when compared to the C57 strain (Fig. 2.4), which suggests
a reduced ability to synthesize GSH efficiently and recycle GSSG to GSH. Gclm
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knockout mice exhibited more extensive hepatic damage when overdosed with
acetaminophen compared to wild-type mice (McConnachie et al., 2007). In addition,
mice with suboptimal levels of Gsr are more prone to oxidative stress and its associated
diseases (Harvey et al., 2009). Thus, overall, our findings suggest the BTBR strain will
be more vulnerable to xenobiotic induced neurotoxicity due to the decreased mRNA
expression of Gclm and Gsr. With this in mind, it has been demonstrated that SJL/J
strain, a mouse model of autoimmunity, showed decreased levels of cortical GSH
levels, decreased EAAT3 levels in CD4+ T cells and decreased levels of methionine
synthase activity in the cortex upon thimerosal exposure (Waly et al., 2012). This
suggests that decreased EAAT3 levels lead to diminished GSH antioxidant capacity
during an oxidative insult, which may alter pre/postnatal epigenetic regulations via
decreases in methionine synthase.
The role of EAAT3 during brain development needs further investigation and the
BTBR mouse strain may be a favorable animal model to study it’s potential involvement
in autism pathophysiology. We found that the BTBR strain contains 2 polymorphisms in
the open reading frame upstream of the coding region (5’) of the mRNA when compared
to C57 mice. The untranslated region (UTR) of mRNA contains short sequence
elements that typically control posttranscriptional regulation, and upstream open reading
frames (uORF) have been demonstrated to reduce protein levels in approximately 100
eukaryotic genes (Calvo et al., 2009). Additionally, three human diseases are known to
be caused via a mutation in the uORF (Liu et al., 1999; Wen et al., 2009; Wiestner et
al., 1998), and a handful of diseases have been tentatively linked to mutations in the
uORF that have been detected in patients but have yet to be tested with population
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controls (Calvo et al., 2009). SNP analysis of EAAT3 additionally reported many
upstream gene variants in the BTBR mouse strain when compared to that of C57 (Fig.
2.7). De novo CNVs (Copy Number Variants) reportedly appear more frequently in
autism spectrum disorders (ASD) than controls and likely develop in the germ line,
making these CNVs unidentifiable in genetic studies with a familial design (Voineagu,
2012). SNPs that are reported to be associated with ASD are regularly located in the
intergenic region of DNA (Voineagu, 2012), thus providing further support of EAAT3
involvement with ASD. However, due to complex nature of autism and the likelihood
that ASD involves multiple genome-environment interactions, it is critical to determine if
the SNP found in the uORF of EAAT3 in the BTBR mouse strain (and all uORF
mutations in general) is influenced and/or regulated via both environmental conditions
and signaling pathways (Voineagu, 2012). It has been suggested that oxidative stress
subsequently affecting the cytosolic GSH/GSSG ratio could result in S-glutathionylation
of various proteins and apoptosis (Daniel et al., 2011), although our data show no
significant changes in the ratio between the two strains. However, in support of our
findings, reactive oxygen species and oxidative stress have been shown to significantly
increase protein failure rates and unfolded protein numbers (Daniel et al., 2011).
Furthermore, redox fluctuations in the intracellular region has been shown to affect gene
translation (Aoyama et al., 2015); additionally, oxidative stress has been previously
reported to reduce EAAT3 activity (Waly et al., 2012).
With EAAT3 protein expression being reduced (Fig. 2.5 and 2.6), and mRNA
concentrations remaining at normal levels in the BTBR strain (Fig. 2.8), it is possible
that oxidative stress caused by improper sulfation subsequently effects the protein
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product and not the mRNA transcribed. However, EAAT3 is immensely regulated via
neuronal activity and intracellular signaling pathways, such as PI3K, and such
regulation can occur both post-transductionally and post-translationally (Nieoullon et al.,
2006). Additionally, SNP analysis further verifies post-transcriptional modification due to
EAAT3 showing a polymorphism in the post-transcriptional regulatory area (5’ upstream
of the coding region) (Fig. 2.7). These data suggest that the mRNA levels of EAAT3
observed in the BTBR strain do not correlate with EAAT3 protein expression, and that
the reduced protein expression observed occurs post-transcriptionally. Moreover, it is
evident that our sample size was not adequate enough to give a power for this particular
experiment; thus, there may be changes in mRNA expressions of EAAT3 with larger
number of samples. The regulatory molecules of EAAT3 need to be further elucidated to
determine their role in EAAT3 transporter protein expression and function.
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CHAPTER 3
Early exposure to APAP induces changes in adolescent mice

3.1 Introduction
Autism is a neurological developmental disorder that occurs in early years of life
and lasts lifetime. Autism is characterized by deficits in social interaction and
communication, as well as restricted and repetitive behavior (Kidd, 2002; Klaiman et al.,
2015). Furthermore, autistic individuals may have other comorbidities (i.e., intellectual
disabilities and depression), which can add to the burden of caregivers managing the
patients’ challenge to carry out normal daily life (Bitsika et al., 2015). Due to the
heterogeneity and complexity of the disease, prevention and cure for autism remains
elusive. Therefore, autistic individuals and their families suffer from economic burden to
provide special education and behavioral intervention in addition to basic medical needs
(Bitsika et al., 2015; Chauhan et al., 2015; Klaiman et al., 2015). There are several
genes that are associated with the development of autism, although it is strongly
suggested that autism may be caused in concert with genetic, biological and
environmental factors (Geier et al., 2009; Rossignol et al., 2012).
Early acetaminophen (APAP) exposure is one of the environmental factors that is
suggested to be linked to autism etiology. Epidemiological studies indicate that chronic
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exposure to APAP during pregnancy may be associated with autism and ADHD-like
behavior (Andrade, 2016; Avella-Garcia et al., 2016; Liew et al., 2014; Thompson et al.,
2014). Reports also suggest that there is an association between APAP administration
in early childhood and developmental disorders, including autism (Bauer et al., 2013;
Schultz et al., 2016; Shaw, 2013). Additionally, it was shown that chronic APAP
administration caused alterations of amino acids levels in brain (Blecharz-Klin et al.,
2014), implicating that APAP can affect neurotransmission and it may lead to changes
in normal brain function. Furthermore, APAP exposure can induce oxidative stress and
mitochondrial dysfunction (da Silva et al., 2012). Taken together, this evidence suggest
that APAP administration may alter homeostasis in brain, and may be involved in
neurobehavioral changes. However, more thorough investigations are essential to prove
the link between APAP exposure and neurodevelopment.
It is well known that the BTBR T+tf/J (BTBR) mouse strain mimics autism
spectrum disorder (ASD) phenotypes and it exhibits three core behavioral symptoms:
impaired social interaction, anxiety, and repetitive behavior. BTBR mice also have a
complete lack of the corpus callosum (Blanchard et al., 2012; Meyza et al., 2012; Meyza
et al., 2013), and reduced heparin sulfate in the subventricular zone (SVZ) of the lateral
ventricles (LV) (Blanchard et al., 2012; Mercier et al., 2012; Meyza et al., 2012). In
chapter 2, we reported that BTBR strain had significantly lower plasma sulfate levels, as
well as lower EAAT3 expression in the frontal cortex compared to the C57 strain.
Sulfation is the major metabolic pathway for APAP clearance, especially in the pediatric
population (Miller et al., 1976). Moreover, lower levels of EAAT3 expression suggests
that cysteine cannot be readily transported from extracellular space as needed. Based
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on this data, we hypothesized that lower sulfate levels and EAAT3 expression would
increase susceptibility to APAP toxicity, thereby exacerbating autistic features in BTBR
strain compared to the C57 strain. To determine the changes with APAP administration,
we injected APAP to neonatal mice and assessed changes in behaviors at adolescent
age.

3.2

Materials and methods

3.2.1

Animal housing and maintenance
All animal experiments were approved by the USF institutional Animal Care and

Use Committee (IACUC). Breeding pairs of C57 BL/6 (C57) and BTBR mice were
obtained from Jackson Laboratory (Bar Harbor, ME). Animals were housed in an animal
facility of the University of South Florida (USF). All animals were given standard chow
and water ad libitum.

3.2.2 Drug treatments
One female mouse per male mouse was kept in same cage for mating and the
presence of plug was checked regularly to confirm gestation. Pregnant mice were
separated from the male mice and kept in new cages. Starting at 7 postnatal days
(PND), pups were treated with APAP. 100 mg/kg APAP (APAP100) or phosphate
buffered saline (PBS) as a vehicle were administered or via intraperitoneal (I.P.)
injection daily for 7 days. The exact doses were calculated based on body weights
measured a day ahead of the drug administration. Following the drug administration
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period, mice were weaned at 21 PND and housed until 3 month old age for behavioral
tests. After the behavioral tests, mice were scarified and plasma and brain samples
were collected for further analysis.

3.2.3 Open Field
The open field test was used as a standard test of general locomotor activity.
Animals were monitored over a 15 min period, under moderate lighting conditions, in a
40-cm square open field arena and assessed using ANY-maze video tracking software
(Stoelting Co., Wood Dale, IL). General locomotor activity levels were evaluated by
measurements of time mice spent during exploration of the open field arena. For
horizontal activities, the total distance, the distance in the center of the arena, and the
time spent in the center of the arena were analyzed using the data collected from the
software. Additionally, the time spent during rearing and grooming were hand scored
from videos.

3. 2.4 Elevated Plus Maze
Anxiety levels were assessed through the elevated plus maze (EPM). The EPM
apparatus consists of two open arms (35 cm) and two enclosed arms (30.5 cm) each
facing each other. Each arm is attached to a center platform (4.5 cm square) and
elevated 40 cm off the floor. The mouse was placed in the center platform and allowed
to explore for 5 min. Video tracking software measured movements in each section and
arm entry determined when 100% of the body enter the arm.
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3.2.5 Social Interaction
The test mouse was first placed in the center chamber of a three-chambered
apparatus and allowed to explore the entire chamber for a 5 min habituation period with
the doorways into the two side chambers open. For sociability test, the test mouse was
enclosed in the center compartment and a novel mouse (an unfamiliar mouse of the
same strain and gender) was enclosed in one of two wired cups positioned in each of
the side chambers. The doors were re-opened and the subject mouse was allowed to
explore the entire box for 10 min. For social novelty test, doors were closed and another
novel mouse was placed in the wired cup in the opposite side of chamber. The doors
were re-opened and the subject mouse was allowed to explore for another 10 min. Data
were collected manually by two un-biased observers by measuring the time spent in
each chamber during both sociability and social novelty sessions.

3.2.6 Fear Conditioning
Fear conditioning was used to assess associative memory function. Mice were
placed in a 25 cm x 25 cm chamber with a wire grid flooring. During training session,
mice were paced in the chamber for 7 min and freezing behavior was monitored
throughout all testing phases. At 3 min and 5 min, mice received a mild foot shock (0.5
mA, unconditioned stimulus) for the last 2 sec of a 30 sec tone (80 db tone, acoustic
conditioned stimulus). 24 hr after the training session, mice were tested again for 3 min
without stimuli for contextual test. After that, we placed the mice in a novel context to
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perform a cued test. During the cued test, mice were allowed to explore the novel
chamber for first 3 min followed by 3 min with acoustic tone. Freezing behavior was
determined when mice present lack of motion for at least 2 consecutive sec.

3.2.7 EAAT3 expression by immunoblotting
We performed Western blotting to test changes in EAAT3. Tissues were
homogenized in ice-cold lysis buffer (Sigma-Aldrich, St. Louise, MO) on ice.
Homogenates were centrifuged at 14,000 g for 20 min at 4 C and the supernatant was
obtained for protein quantification and other experiments. Protein concentration was
determined using the bicinchoninic acid assay (PierceTM BCA protein assay kit, Pierce
Biotechnology, Rockford, IL) for normalization. 30 μg protein was loaded onto 10%
SDS-PAGE gels, then transferred onto nitrocellulose membrane followed by 1 hr
blocking with 5% non-fat dry milk in PBS. Membranes were incubated with rabbit antiEAAT3 antibody (MABN1129, Sigma-Aldrich, St. Louis, MO) and mouse anti-β tubulin
(ab7792, Abcam, Cambridge, MA) overnight at 4 C. After washing with 0.1% Tween 20
containing PBS, membranes were incubated with secondary antibodies for 1 hr and
visualized with Odyssey® Infrared Imaging system (LI-COR Biotechnology, Lincoln, NE).
Band intensities of EAAT3 were normalized to β-tubulin bands as a loading control.

3.2.8 EAAT3 expression by immunohistochemistry
For immunostaining, sagittally transected brains were fixed overnight in 4%
paraformaldehyde (PFA) at 4 C. Samples were then transferred to 30% sucrose
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solution until the tissues no longer float. The brains were cryo-sectioned into 30-μm
thick sections. Tissue sections were blocked with 4% normal goat serum and incubated
with rabbit anti-EAAT3 antibody (1:1000, Sigma-Aldrich, St. Louise, MO) and mouse
anti-NeuN antibody (1:2000, Abcam, Cambridge, MA) overnight at 4 C. Tissues were
washed with 0.1% Triton x-100 containing PBS for 10 min three times. Tissues were
incubated with Alexa fluor 488 conjugated goat anti-rabbit and Alexa fluor 594
conjugated goat anti-mouse secondary antibodies for 1 hr at room temperature. Tissues
were mounted with VECTASHIELD DAPI hardset mounting media (Vectorlab,
Burlingame, CA). Fluorescence images were obtained with Zeiss microscope at 20X
magnification.
To quantify the expression levels of EAAT3 and NeuN, tissue slides were
scanned using a slide scanning microscope (Zeiss). Obtained digital images were
analyzed using Zeiss Neuroquant IAE analysis software. Regions of interest (ROI) were
drawn on the slide images to assess frontal cortex and hippocampus areas. An
experimenter defined thresholds of positive pixel intensity for both 488 and 597
channels to determine positive staining within the given areas. Each tissue was
automatically analyzed based on the threshold setup using a batch processing tool. The
mean positive area within ROI was quantified by the software and used to compare ratio
of EAAT3 expression to the expression of NeuN.
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3.2.9 Statistical analysis
Data are presented as mean ± SEM. In the most cases, comparisons were made
between strains and drug treatments by Two-way ANOVA analysis followed by
Bonferroni post-hoc test. Otherwise, another test is specified as needed. A value of p <
0.05 was considered significant. We used the power analysis to determine the sample
size of 16 per group for each strain (C57 and BTBR) to result at least 80% power, at αlevel of 0.05.

3.3

Results

3.3.1 Effect of neonatal APAP exposure on behavioral phenotypes in adolescence
To determine if neonatal APAP exposure causes a behavioral phenotype in
adolescent age, we administered APAP 100 mg/kg on 7 PND and each day thereafter
for a total of 7 days. After the administration period, mice were housed until 3 months
old age. Mice were then subjected to series of behavioral tests including open field,
elevated plus maze, social interaction and fear conditioning. First, we measured general
locomotor activities using open field. 100 mg/kg APAP administration did not cause
changes in general locomotor activities (Fig. 3.1). However, significant differences were
observed between C57 and BTBR mice. BTBR mice travelled significantly longer
distance compare to C57 (***p < 0.001 for vehicle group, *p < 0.05 for APAP100 group).
Also, BTBR mice showed significantly increased distance travelled in the center zone
(*p < 0.05 for vehicle). High activity levels in the center zone of the open field area
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indicate lower anxiety level (Heredia et al., 2014; Prut et al., 2003). We also performed
EPM to further validate this finding. As a result, BTBR mice showed a trend of lower
anxiety in the vehicle group, and showed significantly lower anxiety levels in APAP100
group (**p < 0.01) compare to the same group of C57 mice (Fig. 3.2). Furthermore, we
manually collected data on spontaneous vertical activities by measuring total time in
rearing and total time in self-grooming from videos produced by the ANY-Maze program.
While APAP exposure did not cause changes compared to the vehicle, the total rearing
time (Fig. 3.1D) was significantly decreased in BTBR mice compare to C57 in both
vehicle and APAP100 groups (C57 vs. BTBR, ***p <

0.001). Also, the time spent

grooming (Fig. 3.1E) was also measured and showed that BTBR mice spent
significantly longer time self-grooming in APA100 groups (C57 vs. BTBR, *p < 0.05).
Amongst the behavioral symptoms of autism, impairment in social skills is the
core behavioral deficit and it is often used as a diagnostic criteria to distinguish from
other neurodevelopmental disorders (Deckers et al., 2014; Holloway et al., 2014). To
determine whether neonatal APAP exposure leads to exacerbated autistic features
during adolescence, we performed the three-chambered social interaction test. Overall,
100 mg/kg APAP did not cause changes in social behavior compared to vehicle in both
C57 (Fig. 3.3A) and BTBR mice (Fig. 3.3B). During the sociability test that assessed if
the subject mouse interacts with the stranger mouse, we found that BTBR mice spent
less time in the side of chamber with the stranger mouse than in the empty chamber
regardless of treatment groups (*p < 0.05). The behavioral phenotypes of BTBR mice
have been studied extensively, and our finding was comparable with others (Blanchard
et al., 2012; Scattoni et al., 2013; Sforazzini et al., 2014). In the social novelty session, a
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new stranger mouse was placed in the empty cage while the old/familiar stranger
mouse stayed in the same side of chamber. As a result, the time spent with familiar
mouse and new stranger mouse were similar in both C57 (Fig. 3.3C) and BTBR mice
(Fig. 3.3D), regardless of drug treatment groups.
We also performed fear conditioning test to determine associative memory
function by exposing mice to the auditory cue (tone, conditioned stimulus) and aversive
stimulus (electric foot shock, unconditioned stimulus). The fear memory is assessed by
the amount of freezing behavior, operationally defined as 2 sec of complete inactivity
and stillness. During training session, the freezing behavior was comparable between
C57 (Fig. 3.4A) and BTBR (Fig. 3.4B) strains, as well as between drug treatment groups.
During the contextual fear conditioning test (Fig. 3.4C), BTBR mice demonstrated
significantly lower freezing behaviors compared to C57 mice in both treatment groups
(***p < 0.001). In addition, BTBR strain also showed lower freezing behaviors overall
during cued fear conditioning test (Fig. 3.4D) regardless of the presence of the tone
(***p < 0.001). This finding of decreased in associative memory function in BTBR
compared to the control strain is in agreement with others (MacPherson et al., 2008;
Yang et al., 2012).
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Figure 3.1 C57 and BTBR showed unchanged locomotor activities with APAP
exposure. The effects of APAP exposure on general locomotor activities were analyzed
as locomotor. Overall, mice exposed to APAP 100 mg/kg did not show significant
differences in general locomotor activities. However, BTBR strain showed a significant
increase in total distance traveled (A) in the open field compare to C57 in both vehicle
(C57 vs. BTBR, ***p < 0.001) and APAP100 groups (C57 vs. BTBR, *p < 0.05). Also,
BTBR strain showed a significant increase in the distance travelled in the center (B)
compared to C57 vehicle (*p < 0.05), while the time spent in center (C) did not show
significant changes. For spontaneous vertical activities, the total rearing time (D) was
measured and showed significantly lower rearing activities in BTBR mice compare to
C57 in both vehicle and APAP100 groups (C57 vs. BTBR, ***p < 0.001). The time spent
grooming (E) was also measured and showed that BTBR mice spent significantly longer
time self-grooming in APAP100 groups (C57 vs. BTBR, *p < 0.05)
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Figure 3.2 Changes in anxiety levels in C57 and BTBR mice. Both C57 and BTBR
did not show changes in anxiety levels between vehicle and APAP100 groups. However,
BTBR mice that received APAP 100 mg/kg spent significantly longer time in the open
arm compared to C57 mice in same treatment group (**p < 0.01).
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Figure 3.3 Social behaviors of adolescent C57 and BTBR mice. In sociability test (A
and B), C57 mice (A) spent time in the chamber with stranger similar to the empty
chamber regardless of treatment. BTBR (B) showed significant less time spent with
stranger mouse than in the empty chamber both in vehicle (two-tailed t-test, *p < 0.05)
and APAP100 groups (two-tailed t-test, *p < 0.05). Social novelty (C and D) was
assessed using another new stranger mouse and measured the time spent with either
the familiar mouse or new stranger mouse. C57 mice (C) spent similar amount of time in
the chamber with new stranger mouse and with familiar mouse. BTBR mice (D) also
spent similar amounts of time in each chamber, regardless of treatment. In APAP100
group, BTBR spent significantly less time with new stranger mouse compare to C57
(two-tailed t-test, ††p < 0.01)
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Figure 3.4 Differences in contextual and cued fear conditioning between C57 and
BTBR mice. Freezing behavior during the training session is shown in panel A for C57
and B for BTBR, and the freezing behavior is comparable with strains and treatment
groups. Arrows on both panels indicate the time that a tone and a foot shock occurred
(3 min and 5 min). Although there were no differences between treatment groups in
both C57 and BTBR mice with the contextual fear conditioning test (C), BTBR mice
showed significantly less freezing behaviors compare to C57 mice in both treatment
groups (***p < 0.001). Similarly, APAP did not affect freezing behavior during the cued
conditioning test in both strains, but BTBR showed significantly reduced freezing
behavior compared to C57 regardless of the presence of the tone (***p < 0.001).
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3.3.2 Effect of neonatal APAP exposure in EAAT3 expression levels in adolescence
In chapter 2, we reported that BTBR strain had significantly lower EAAT3
expression levels in frontal cortex. Based on this observation, we determined if early
exposure to APAP caused differences in EAAT3 expression levels in frontal cortex as
well as in hippocampus. To assess EAAT3 expression, we immunostained brain tissues
with EAAT3 and NeuN (neuronal marker) together (Fig. 3.5, 3.6 and 3.7), and we also
performed western blotting to further validate our findings (Fig. 3.8).
We compared C57 (Fig. 3.5A) and BTBR (Fig. 3.5B) mice. BTBR showed
decreased EAAT3 expression levels in both the frontal cortex (Fig. 3.5C, two-tailed ttest, *p < 0.05) and hippocampus (Fig. 3.5D, two-tailed t-test, **p < 0.01). It has been
reported that EAAT3 expression was high in the hippocampus and the neurons in
hippocampus were more vulnerable to oxidative stress (Aoyama et al., 2006). This
finding is also in agreement with our western blot data (Fig. 3.8) showing significantly
decreased EAAT3 expression levels in brain homogenate of BTBR mice compared to
C57 mice.
Next, we compared vehicle and APAP100 groups in each strain. For C57 mice
(Fig. 3.6), there were no significant changes in both the frontal cortex and the
hippocampus, a finding supported by our western blot data (Fig. 3.8). While the
APAP100 group of the C57 strain seemed to have lower EAAT3 expression than the
vehicle, it was not significant (t-test, p = 0.0674). Parallel to this experiment, we also
measured EAAT3 expression in BTBR mice to determine if APAP administration caused
changes in the expression levels of EAAT3. As a result, APAP100 group showed
significantly elevated EAAT3 in both the frontal cortex (Fig 3.8C, t-test, *p < 0.05) and
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the hippocampus (Fig. 3.8D, t-test, *** p < 0.001) compare to vehicle. Similarly, BTBR
showed elevated EAAT3 expression levels in APAP100 in hippocampus (Fig. 3.8B).
These findings suggest that early exposure to APAP even at the therapeutic doses may
alter normal brain development, with changes still evident in adolescence.
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Figure 3.5 EAAT3 and NeuN expression in the frontal cortex and hippocampus of
C57 and BTBR mice. Images from C57 (A) and BTBR (B) are shown (20X, 100X
magnification). The quantification of EAAT3 expression was calculated by ratio of
EAAT3 signal intensity to NeuN signal intensity. As a result, BTBR showed significantly
reduced EAAT3 expression compared to C57 in both the frontal cortex (FC, panel C,
two-tailed t-test, *p < 0.05) and the hippocampus (HC, panel D, two-tailed t-test, **p <
0.01). Scale bar = 50 μm.
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Figure 3.6 EAAT3 and NeuN expression in C57 mice. Images from C57 mice with
vehicle group (A) and APAP100 group (B) are shown. Results showed that there were
no significant changes between vehicle and APAP100 groups both in the frontal cortex
(FC) (C) and the hippocampus (HC) (D). Scale bar = 50 μm.
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Figure 3.7 EAAT3 and NeuN expression in BTBR mice. Images from BTBR mice
with vehicle group (A) and APAP100 group (B) are shown. Results showed that the
expression of EAAT3 was significantly increased in APAP100 group in both the frontal
cortex (FC, panel C, two-tailed t-test, *p < 0.05) and the hippocampus (HC, panel D,
two-tailed t-test, ***p < 0.001). Scale bar = 50 μm.
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Figure 3.8 Expression of EAAT3 and NeuN levels in brain homogenates. In the
frontal cortex (A), there were no changes in the EAAT3 expression between vehicle and
APAP100 groups both in the C57 and BTBR mice. However, vehicle group of the BTBR
mice showed significantly lower EAAT3 expression levels compared to the vehicle
group of C57 mice (*p < 0.05). In the hippocampus (B), there were no differences
between vehicle and APAP100 group in C57 mice. The APAP100 group of BTBR
showed significantly elevated EAAT3 expression levels compared to vehicle group (*p <
0.05). In addition, the vehicle group of BTBR showed significantly lower EAAT3
expression level compared to the vehicle group of C57 (†p < 0.05).
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3.4

Discussion
In this chapter, we demonstrated that neonatal APAP exposure changes in

behavioral phenotypes and EAAT 3 expression during adolescence. We also showed
that the changes are greater in the BTBR mouse strain compared to C57 due to the
lower plasma sulfate levels and EAAT3 expressions in brain. As our results show, we
did not observe significant differences in mouse behaviors in adolescent mice between
vehicle groups and APAP100 groups of both strains. This may be due to the dose of
APAP used in our experiments.
For example, a study showed significant changes in brain amino acid levels after
long-term administration with APAP at therapeutic dose in Wistar rats; which may be an
important evidence that APAP administration may alters neurotransmission in the brain
leading to abnormal behavioral phenotypes (Blecharz-Klin et al., 2014). Also, it was
suggested that acute administration of repeated doses of APAP at the therapeutic dose
range at PND 10 caused alterations in locomotor activities in adulthood as well as
changes in brain derived neurotrophic factor (BDNF) in different regions of brain at PND
10 (Viberg et al., 2014). Taken together, these findings suggest that APAP
administration alters essential factors during normal brain development and it may lead
to abnormal behaviors. There was a recent study that tested acute exposure to 100
mg/kg APAP at 3 to 4 month old age, and showed increases in social behavior in these
BTBR mice (Gould et al., 2012). Even though this study reported the opposite effects of
APAP in BTBR mice with the increase in social behavior, it is still relevant to current
study as it demonstrates that acute APAP exposure at the therapeutic dose alters
behavioral changes. We may see a discrepancy since the experimental design of the
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above study differed from the current study. The above study used acute exposure and
tested behaviors within 1 hr. This change in assessment time could lead to robust and
more evident behavioral changes, compared to our 3-month analysis point. Thus the
100 mg/kg changes may induce immediate changes, but possibly not sustained after a
longer period of time (i.e. 3 months).
We then measured EAAT3 expression in the frontal cortex as well as in the
hippocampus to assess if EAAT3 expression is altered in response to APAP exposure.
Overall, early exposure to APAP caused elevated EAAT3 expression in the frontal
cortex and hippocampus in the BTBR mice, but not in the C57 strain. This finding may
be a compensatory mechanism to increase intracellular cysteine levels for GSH
production.
We also compared the EAAT3 expression and behavioral phenotypes of the C57
and BTBR mice. First, we were able to validate the findings from chapter 2 showing
lower expression levels of EAAT3 in the frontal cortex and hippocampus. In addition,
although we were not able to show significant changes with 100 mg/kg APAP
administration, we observed differences in behavioral phenotypes between C57 and
BTBR mice. With open field test, BTBR mice showed elevated repetitive behaviors as
shown in self-grooming behavior. Also, we observed lower anxiety levels in BTBR mice.
These results are in agreement with others (Amodeo et al., 2012; Molenhuis et al.,
2014). BTBR strain is known to have architectural abnormalities with corpus callosum
agenesis and reduced hippocampal commissures, the brain regions that connect both
hemispheres and hippocampi, respectively (Bohlen et al., 2012; Sforazzini et al., 2014;
Wahlsten et al., 2003). These architectural abnormalities have been reported to be
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associated with less responsiveness in contextual and cued fear conditioning
(MacPherson et al., 2008; Schimanski et al., 2002). We also determined that BTBR
strain tends to show less freezing behavior in both contextual and cued fear
conditioning; suggesting impaired associative memory in BTBR mice.
There have been an increasing number of human association studies that link
APAP exposure and autism; suggesting prenatal exposure to APAP causes
hyperactivity and attention deficit (Andrade, 2016; Avella-Garcia et al., 2016; Becker et
al., 2010; Liew et al., 2014; Thompson et al., 2014) . Although our finding did not
support the hypothesis that early APAP exposure at therapeutic doses causes autistic
like behavior in mice during adolescence, they will be important to consider in designing
future investigations.
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CHAPTER 4
Acetaminophen induced toxicity in neonatal mice

4.1

Introduction

As described in chapter 1, acetaminophen (APAP) is one of the most popular
over-the-counter drugs that possesses both antipyretic and analgesic effects. It is
considered a relatively safe and effective pharmaceutical agent when used at
recommended therapeutic doses. However, intentional/unintentional overdose and
chronic use of APAP can cause serious skin reactions, liver failure, and even death
(Botting, 2000; Dahlin et al., 1984).
Approximately 10 to 15% of APAP is metabolized by cytochrome P450 2E1 (CYP
2E1) to a highly electrophilic and toxic metabolite, N-acetyl-para-benzoquinoneimine
(NAPQI). NAPQI covalently binds with the major endogenous antioxidant found in the
body, glutathione (GSH), and as a result, NAPQI depletes available GSH stores.
Excessive amounts of NAPQI can bind to DNA and proteins leading to cellular damage
(Copple et al., 2008; Kalinec et al., 2014; Moore et al., 1985). Another metabolite, paminophenol (4AP), is produced by deacetylation of APAP by the liver and can be found
in the liver, kidney and brain. Emerging evidence shows that APAP can cross the bloodbrain-barrier (BBB) and cause neurotoxicity through its metabolites (Gould et al., 2012;
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Hogestatt et al., 2005). However, the mechanism of 4AP-induced toxicity is not clear,
especially in the brain (McConkey et al., 2009).
The brain is more prone to oxidative stress because of its high oxygen
consumption rate; this leads to increased free radical production. Being composed of a
high concentration of polyunsaturated fatty acids also makes it a target for lipid
peroxidation. The availability of major endogenous antioxidants, such as GSH, is
important to balance redox homeostasis. As NAPQI and 4AP are known to deplete GSH
in the liver and kidney, it is possible that APAP administration will dose-dependently
disrupt GSH homeostasis in the brain resulting in increased oxidative stress.
APAP may adversely affect the brain, particularly during early development,
when it is prescribed to children to lessen fever or irritability after vaccination during the
first year of life. While there is evidence for cytotoxic effects of APAP and its metabolites
in cultured cortical neurons (Schultz et al., 2008), it is unclear if APAP exerts its effects
on the brain during development and how this may lead to developmental disorders.
Based on the existing evidence, we hypothesized that early exposure to APAP
administration will dose-dependently induce cellular damage and oxidative stress by
disrupting GSH homeostasis. To test this hypothesis, we used C57 and BTBR mouse
strains for early exposure to APAP administration. In human studies, the half-life of
APAP was prolonged in neonates and younger children compared to adults, which
increased the chance for its accumulation in the plasma (Arana et al., 2001). This study
also indicated that repeated doses over short time periods may cause high APAP
plasma levels, which could be toxic due to accumulation of its metabolites, NAPQI and
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4AP. In this study, we determined if sub-chronic doses of APAP administration induce
neurotoxicity in vivo.

4.2

Materials and methods

4.2.1 Animal housing and maintenance
All animal experiments were approved by the USF institutional Animal Care and
Use Committee (IACUC). Breeding pairs of C57 BL/6 (C57) and BTBR mice were
obtained from Jackson Laboratory (Bar Harbor, MA). Animals were housed in the
animal facility at the University of South Florida (USF). All animals were given standard
chow and water ad libitum.

4.2.2 Drug treatments
One female mouse per male mouse was kept in same cage for mating and the
presence of plug was checked regularly to confirm gestation. Pregnant mice were
separated from the male mouse and kept in new cages. Starting at 7 postnatal days
(PND), pups were treated with APAP. Animals were administered with phosphate
buffered saline (PBS) as a vehicle, 100, 200 and 300 mg/kg APAP via intraperitoneal
(I.P.) injection daily for 7 days. The exact doses were calculated based on body weights
measured a day ahead of the drug administration.
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4.2.3 Tissue preparation
Mice were sacrificed approximately 2 hours from the last drug administration.
Syringes were coated with EDTA to collect blood samples via cardiac puncture. Blood
samples were transferred to clean tubes and centrifuged at 14,000 g for 15 min to
obtain plasma. Brain tissues were collected and frozen immediately in liquid nitrogen.
All samples were kept in -80 C until assays. Tissues were homogenized in ice-cold
lysis buffer (Sigma, St. Louis, MO) on ice. Homogenates were centrifuged at 14,000 g
for 20 min at 4 C and the supernatant was collected for protein quantification and other
experiments. Protein amount was determined using the bicinchoninic acid assay
(PierceTM BCA protein assay kit, Pierce Biotechnology, Rockford, IL) for normalization.

4.2.4 ALT assay
Alanine aminotransferase (ALT) activity was measured using ALT fluorometric
assay kit (BioVision, Inc., Milpitas, CA) following the manufacturer’s instructions.
Plasma samples were diluted in assay buffer; 20 μL of the samples and standards were
loaded onto a 96 well microplate. Following, 100 μL of the enzyme and substrate
mixture was added to each well. Fluorescent intensity was measured using a microplate
reader at 535/587 nm (Ex/Em). The plate was read at 5 min (T1) and at 60 min (T2)
after incubating the plate at 37 C. The obtained fluorescent intensity units were
calculated based on the pyruvate standard curve and converted to nmol of pyruvate.
The obtained pyruvate amount was divided by (time x initial sample volumes) to
calculate enzyme activity.
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4.2.5 AST assay
Aspartate aminotransferase (AST) activity was measured using AST activity
colorimetric assay kit (BioVision, Inc., Milpitas, CA) according to the manufacturer’s
instructions. Brain homogenates and plasma samples were loaded onto a 96-well plate.
Reaction mixture composed with AST substrate, AST enzyme and AST developer were
added and optical density was measured at 450 nm. Optical density was measured at 5
min (T1). The plate was incubated at 37 C for 60 min (T2) and optical density was
measured again. As a product of this enzyme reaction, glutamate was used as a
standard. The generated glutamate from each sample was calculated based on the
glutamate standard curve and the amount was divided by (time x initial sample
volumes) to calculate enzyme activity.

4.2.6 GSH/GSSG assay
Total and reduced GSH was measured using glutathione fluorescent detection kit
(Arbor AssaysTM, Ann Arbor, MI) according to the manufacturer’s instructions. First,
frozen tissues and plasma samples were thawed on ice. Brain tissues were gently
rinsed with ice-cold PBS and the right hemispheres were homogenized with ice-cold
100 mM phosphate buffer (pH 7.0). Homogenates were centrifuged at 14,000 g for 10
min at 4 C and supernatants were collected. 5% sulfosalicylate was added to each
aliquoted sample (both tissue homogenates and plasma) and incubated on ice for 10
min followed by centrifugation for deproteination. Supernatant was collected and diluted
with assay buffer. 50 μL of samples and standards were plated onto a 96 well plate and
25 μL of the ThioStar® reagent was added to measure reduced GSH concentration.
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Fluorescent readings were obtained at 510/370 nm (Ex/Em) after incubating for 15 min
at room temperature. For total GSH, 25 μL of a reaction mixture (glutathione reductase
and NADPH) was added to convert GSSG to GSH. Treated samples were allowed to
react for 15 min at room temperature and fluorescent signals were read again. GSSG
concentrations were calculated by subtracting the amount of reduced GSH from the
amount of total GSH and dividing by 2.

4.2.7 GPx activity assay
Glutathione peroxidase (GPx) enzyme activity was measured using GPx assay
kit (BioVision, Inc., Milpitas, CA) following manufacturer’s instruction. In this assay, GPx
reduces Cumene hydroperoxide while oxidizing GSH to GSSG. The GSSG is reduced
back to GSH by glutathione reductase using NADPH as a proton donor. The decreased
NADPH is measured at 340 nm and is proportional to GPx activity.

4.2.8 GST activity assay
Glutathione-s-transferase (GST) activity was measured using GST assay kit
(Sigma-Aldrich, St. Louis, MO). In this assay, GST conjugates glutathione and 1-Chloro2,4-dinitrobenzene (CDNB). Brain homogenates and plasma samples were loaded onto
a 96-well plate, and the mixture of CDNB and GSH was added to start the enzyme
reaction. Absorbance was measured at 340 nm at 0 min (T1) and 60 min (T2). The
increased absorbance is proportional to GST enzyme activity and the difference
between T2 and T1 is divided by the reaction time.
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4.2.9 Enzyme-linked immunosorbent assay (ELISA) for HNE adducts
4-hydroxy-2-nonenal (HNE) is one of the biomarkers of lipid peroxidation and it is
an indicative of elevated oxidative stress. HNE adducts were measured using
OxiSelectTM HNE adduct competitive ELISA (Cell Biolabs, Inc., San Diego, CA) per
manufacturer’s instruction. Brain homogenates were loaded onto a HNE conjugate
coated plate. After 1 hour incubation with anti-HNE polyclonal antibody, HRP
conjugated secondary is added. After visualization with substrate solution, absorbance
was measured at 450 nm. The amount of HNE adducts were calculated based on the
standard curve generated using HNE standards. Also, data was normalized by total
protein amount determined by BCA protein assay.

4.2.10 Statistical Analysis
Data was presented as mean ± standard error of mean (SEM). Analysis of
variance (ANOVA) was used, followed by post hoc comparison using Bonferonni’s
method for multiple variables.

The α-levels were set at 0.05 for all analyses. The

GraphPad version 5.0 was used for statistical analysis and to assess significance within
the data.
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4.3

Results

4.3.1

APAP administration causes toxicity in neonatal mice

Mice were exposed to three different doses of APAP (APAP 100, 200 and 300
mg/kg) and vehicle starting at postnatal day 7 (PND 7). APAP was administered daily
via I.P. injection for 7 days. The three doses were calculated based on the equation
which uses standardized conversion factors for body mass (FDA, 2005). APAP 100
mg/kg (APAP100) is considered to be safe; while 200 mg/kg is seen as a high dose, but
still falls in the range of a safe dose. APAP administered at 300 mg/kg is a toxic dose in
infants. The toxicity of APAP was determined by calculating mortality rate (Fig. 4.1)
which was done by Kaplan-Meier analysis with a log-rank test. During the 10-day
observation period, both C57 (Fig. 4.1A) and BTBR (Fig. 4.1B) mice showed
significantly increased mortality rate at 200 and 300 mg/kg groups in a dose dependent
manner (***p < 0.001). The groups that received the toxic dose of APAP (300 mg/kg) in
both C57 and BTBR showed the highest mortality rate at 100% (n = 11) and 69.23% (n
= 13), respectively. The mice receiving 200 mg/kg of APAP showed mortality rate at
61.5% (n = 13) and 37.5% (n = 16) for C57 and BTBR. In the lowest dose group of
APAP100, C57 showed 16.67% (n = 12), while BTBR showed 0% mortality rate at the
same dose (n = 15). Both vehicle groups did not show mortality. Based on this result,
our working dose was adjusted to 100 mg/kg as higher doses caused fatality. Later, 150
mg/kg dose group was added as 100 mg/kg dose did not show increased toxicity levels.
To investigate if the repeated doses increased toxicity of APAP, both plasma and
brain homogenates were collected at day 1 and day 7. ALT and AST levels were
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measured to determine APAP induced liver damage using plasma. While ALT is strictly
produced from the liver as a sign of toxicity, AST is produced from other organs as well
including brain (Hertz et al., 2017; Pérez-Mato et al., 2016). ALT levels were similar
between vehicle groups and APAP100 groups in both C57 and BTBR strain, and both at
day 1 and day 7; suggesting no sign of liver toxicity at 100 mg/kg dose. Plasma levels of
AST (Fig. 4.2B) only increased in the APAP100 mg/kg group of BTBR mouse strain at
day 1 compared to vehicle (n = 4, *p < 0.05). In the brain (Fig. 4.2A), the BTBR mice
treated with APAP100 showed significantly elevated AST levels compared to vehicle at
day 1 (n = 4, **p < 0.01) compared to C57 at the same dose (n = 4, ###p < 0.001).
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Figure 4.1 Mortality rate of C57 and BTBR mice with APAP administration. KaplanMeier analysis with a log-rank test was used to compare each treated group (n = 10-16
in each group). Both C57 (A) and BTBR (B) showed significantly increased mortality
rate dose dependently (***p < 0.001).
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Figure 4.2 ALT levels in plasma. Both C57 (A) and BTBR (B) strains showed
unchanged ALT levels between vehicle and APAP100 groups. At day 1, C57 (A)
showed significantly elevated ALT levels in both vehicle and APAP treated groups (n =
4, **p < 0.01) compare to day 7.
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Figure 4.3 AST levels in the brain and plasma. In the brain (A), AST levels were
significantly elevated in BTBR mice that received APAP100 compared to the vehicle (n
= 4, **p < 0.01). Also, the BTBR 100 group showed significantly elevated AST levels
compared to C57 strain which received same dose (n = 4,

###p

< 0.001). In plasma (B),

the BTBR strain that received APAP100 showed significantly elevated AST levels
compared to BTBR vehicle. At day 7, both C57 and BTBR mice showed similar levels of
AST in brain and plasma.
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4.3.2 APAP disturbs GSH homeostasis in neonatal mice

APAP is metabolized in the liver and GSH is associated with detoxification of
APAP and its metabolites as described in Chapter 1; therefore we measured GSH and
GSSG in plasma and brain homogenates. In brain homogenates (Fig. 4.4), GSH and
GSSG levels were not different between groups (Fig 4.4A, first and second panels), but
GSSG (Fig. 4.4A, second panel) was significantly elevated between day 1 and day 7
when treated with APAP100 in C57 (n = 4, **p < 0.01). In BTBR mice (Fig 4.4B), GSH
levels did not fluctuate as seen in C57 mice, but GSSG levels were significantly
elevated between day 1 and day 7 with APAP administration (n = 4, *p < 0.05).
In plasma, GSH levels were also similar between treatment groups (Fig 4.5A and
B, first panels) both in C57 and BTBR. C57 mice, contrary to what we observed in the
brain homogenates, GSSG levels were decreased in APAP100 treated mice compared
to the vehicle (n = 4, *p < 0.05). In addition, the ratio of GSH to GSSG was significantly
increased compared to the vehicle (n = 4, ***p < 0.001), and APAP100 group at day 1
(n = 4, #p < 0.05) due to the decreased in GSSG levels. In BTBR mouse (Fig. 4.5B),
plasma levels of GSH and GSSG showed a trend towards an increase in both GSH and
GSSG at day 7 with APAP100 group, but it was not significantly different.
Even though our data shows some significant changes in GSH and GSSG levels,
it doesn’t show robust changes between treatment groups. Based on the toxicity data
(Fig. 4.1, 4.2 and 4.3), 100 mg/kg dose may not change GSH and GSSG. Therefore, we
chose another dose at 150 mg/kg to confirm if the supratherapeutic dose induced any
changes in GPx, GST enzyme activities and 4-hydroxynonenal (HNE) adducts levels.
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For GPx activity (Fig. 4.6), GPx activities were significantly elevated with 150
mg/kg APAP (APAP150) administration in all groups (n = 4, *p < 0.05, ***p < 0.001);
suggesting that GPx activities were required to convert elevated levels of peroxides with
APAP150 in the brain. In addition, APAP100 group of BTBR showed significantly
decreased GPx activities at day 7 compare to day 1 (n = 4, ‡p < 0.01). Also, APAP100
group in BTBR strain showed significantly elevated GPx activity compare to the same
dose group of C57 (n = 4, †p < 0.05) at day 1. For GST activity (Fig. 4.7), both C57 and
BTBR showed similar levels of GST activity between treatment doses and durations in
brain homogenates (Fig. 4.7A). However, in the plasma (Fig. 4.7B), APAP100 and
APAP150 groups in C57 showed significantly higher GST activity compared to vehicle
(n = 4, *p < 0.05) at day 7; which suggests increased levels of detoxification via GST
with APAP administration. In addition, BTBR APAP150 showed significantly higher GPx
activity compared to C57 (n = 4, †p < 0.05).
Lastly, levels of HNE adducts were measured in the brain homogenates. HNE
adducts levels were significantly elevated in APAP 150 groups compared to the vehicle
(**p < 0.01) and APAP100 groups (*p < 0.05) C57 strain at day 7(A). Also, APAP150
group in BTBR (Fig. 4.8) showed significantly elevated HNE adducts levels at both day1
(*p < 0.05, compare to vehicle) and day 7 (*p < 0.05, compare to APAP100; **p < 0.01,
compare to vehicle). These elevated HNE adducts may indicate that APAP150 may
cause oxidative stress in the brain. Additionally, HNE adducts levels in APAP150 group
were significantly higher in day 7 than in day 1 (††p < 0.01).
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Figure 4.4 GSH, GSSG and GSH/GSSG in pup brain homogenates. C57 mice (A)
showed similar GSH levels, but significantly different GSSG levels between day 1 and
day 7 with APAP treated group (n = 4, **p < 0.01). BTBR mice (B) also showed similar
GSH levels, but showed significantly elevated GSSG level at day 7 compared to day 1
when treated with APAP (n = 4, *p < 0.05). No differences were observed in the ratio of
GSH to GSSG in both C57 and BTBR strains.
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Figure 4.5 GSH, GSSG and GSH/GSSG in plasma. GSH levels were similar in both
C57 (A) and BTBR (B) strains. In C57 strain, GSSG levels were significantly lower in the
APAP100 group at day 7 compared to the vehicle (n = 4, *p < 0.05). Additionally, the
ratio of GSH to GSSG was significantly elevated in the APAP100 group compared to
vehicle at day 7 (n = 4, ***p < 0.001), and compared to APAP 100 group at day 1 (n = 4,
#p

< 0.05).
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‡

†

Figure 4.6 GPx activity assay in pup brain homogenates. Overall, GPx activities
were significantly elevated with APAP150 administration in all groups (n = 4, *p < 0.05,
***p < 0.001). In addition, APAP100 group of BTBR showed significantly decreased GPx
activities at day 7 compare to day 1 (n = 4, ‡p < 0.01). Also, APAP100 group in BTBR
strain showed significantly elevated GPx activity compare to the same dose group of
C57 (n = 4, †p < 0.05) at day 1.
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Figure 4.7 GST activity in brain and plasma. In brain (A), both C57 and BTBR
showed similar levels of GST activity between treatment doses and durations. In plasma
(B), APAP100 and APAP150 groups in C57 showed significantly higher GST activity
compared to vehicle (n = 4, *p<0.05) at day 7. In addition, BTBR APAP150 group
showed significantly higher GST activity compared to C57 at day 1 (n = 4, †p<0.05).
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Figure 4.8 Levels of HNE adducts in the brain after APAP administration. HNE
adduct levels were significantly elevated in APAP150 groups compared to the vehicle (n
= 4, **p < 0.01) and APAP 100 groups (n = 4, *p < 0.05) at day 7 in C57 strain (A). In
BTBR (B), APAP150 group showed significantly elevated HNE adduct levels at day1 (n
= 4, *p < 0.05, compare to vehicle) and day 7 (n = 4, *p < 0.05, compare to APAP 100; n
= 4, **p < 0.01, compare to vehicle). Additionally, HNE adduct levels in APAP150 group
were significantly higher in day 7 than in day 1 (††p < 0.01).
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4.4

Discussion

APAP is recommended after vaccination to reduce fever and irritability in infants
and young children. It is known to safe within the therapeutic doses; however, due to
the repeated doses often used, unintentional overdose, and poor detoxification
capability in pediatric population, APAP induced toxicity in pediatric population has been
reported (Leonis et al., 2013). We postulate that APAP may cause changes in brain,
even with non-toxic doses. We investigated if APAP administration at sub-chronic doses
1) would be toxic to neonatal mice, and 2) if C57 and BTBR mice respond differently to
this treatment due to the diminished plasma sulfate levels and EAAT3 expression levels
in the brain as shown in chapter 2. Pups at 7 PND were treated with APAP at different
doses for 7 days via I.P. injection. In our study, we hypothesize that repeated
physiologically safe doses of APAP would cause changes in the brain.
The human clinical doses for APAP administration are determined based on
weight, especially in the pediatric population. The doses for animals are not well
established in mice, therefore we calculated the experimental doses based on the
formula that uses body mass constant for the dose conversion from animal to human
(FDA, 2005). Children (ages one to two) are recommended within a 24 hour period to
have 5 maximum doses of 10 to 15 mg/kg of APAP (Leonis et al., 2013). Using the
formula, 100 mg/kg animal dose is equivalent to 10 mg/kg human dose. Three doses of
100 mg/kg, 200 mg/kg and 300 mg/kg were chosen and administered for 7 days starting
at 7 PDN. As a result, two higher doses induced high mortality (Fig. 4.1).
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In addition, we showed that APAP100 did not induce tissue damage using ALT
and AST levels (Fig. 4.2 and 4.3). However, there was an increase in AST levels seen
in brain homogenates of BTBR mice. This suggests that APAP induced changes in the
brain without causing liver damage in neonatal BTBR mice. AST is also referred to as
glutamic oxaloacetic transaminase (GOT). In the brain, it is known to play a role in
balancing glutamate homeostasis by degrading glutamate using oxaloacetate as a cofactor; therefore, elevated AST activity has shown to be associated with decreased in
glutamate levels, exerting neuroprotective effect (Pérez-Mato et al., 2016; Teichberg et
al., 2009; Zhang et al., 2016). Perhaps, the elevated AST in the brain homogenates of
BTBR mice is a compensatory mechanism.
Furthermore, we investigated if APAP at the therapeutic doses caused changes
in GSH levels. As stated in chapter 1, APAP is metabolized by CYP 2E1, an enzyme is
also expressed in brain. APAP crosses the blood brain barrier and is known to disrupt
endocannabinoid signaling through another metabolite, para-aminophenol (4AP)
(Dalmann et al., 2015; Hogestatt et al., 2005; Yisarakun et al., 2014). We measured
plasma and brain levels of GSH, GSSG, and its ratio (GSH/GSSG). In C57 mice,
APAP100 did not exert significant changes in GSH levels compared to vehicle in both
plasma and brain (Fig. 4.4 and 4.5). However, GSSG levels were elevated significantly
in brain homogenates at day 7 compared to day 1 (Fig. 4.4), and plasma GSSG levels
were significantly decreased (Fig. 4.5) in C57. GSSG, the oxidized glutathione, is the
by-product generated when GPx converts hydrogen peroxide to water. Therefore,
increased GSSG is associated with elevated oxidative stress. The GSSG is then
reduced back to GSH by glutathione reductase (GR) to maintain GSH pool. The
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decreased GSSG in plasma may be the sign of reduced levels of oxidative stress.
However, elevated GSSG in brain homogenates for both C57 and BTBR mice may
suggest increase in oxidative stress, GPx or GR activity. From our data. There was no
increase in GPx activity with APAP100 in both mouse strains (Fig. 4.6); thus, it may be
linked to GR activity rather than GPx activity. To validate GR activity as a dependent
factor future experiments are needed. Ultimately, 100 mg/kg APAP did not cause
consistent changes in GSH and GSSG levels, therefore we believe that APAP100 is
therapeutically safe. Thus, we included 150 mg/kg dose to determine if a
supratherapeutic dose can change GPx and GST activity. Supratherapeutic dose of
APAP (150 mg/kg) showed significant increase of GPx activity (Fig. 4.6). Also, plasma
levels of GST activities were changed while brain levels were unchanged in both C57
and BTBR. This suggests that 150 mg/kg may be safe but GSH balance may be
affected.
Our ultimate goal of this project was to determine if APAP administration during
neonatal period caused oxidative stress due to the imbalance of the GSH system.
Therefore, we measured HNE adducts levels, which is a lipid peroxidation markers.
HNE levels have been implicated in numerous neurological disorder including autism
(Kwon et al., 2007; Pecorelli et al., 2013; Romano et al., 2017). HNE is produced during
lipid peroxidation by oxidation of n-6 fatty acids and elevated. Our results showed that
HNE adducts were elevated primarily with APAP150 administration at day 7 in both C57
and BTBR. This suggests that supratherapeutic dose of APAP may cause oxidative
stress even though the dose is still considered to be safe. APAP is known to have a
narrow therapeutic index (Budnitz et al., 2011; Claridge et al., 2010), thus erroneous
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dosing may lead to serious side effects. There have been case studies which report
possible side effects of APAP even with therapeutic doses (Claridge et al., 2010; Heubi
et al., 1998; Moling et al., 2006).
Overall, our data supports that APAP administration in children may increase
oxidative stress and also negatively affect the GSH system even with safe doses. While
this study is valuable in urging parents and caregivers to practice safety of APAP dose
administration to young children, more thorough investigations are needed to further
confirm the effects of APAP in the pediatric population.
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CHAPTER 5
Conclusion

Autism is characterized by deficits in social interaction and communication, as
well as restricted and repetitive behavior and are used to diagnose autism (Klaiman et
al., 2015). The underlying cause of autism is still unclear, due to the heterogeneity and
complexity of the disease; hence, it is hard to prevent and cure the disorder. While
behavioral interventions and pharmacological therapies are used to ease the symptoms,
there is still a need for the development of more effective diagnostic tools and therapies.
In fact, the timing of diagnosis is critical for therapy outcomes (Bradshaw et al., 2015;
Webb et al., 2014), especially with behavioral interventions; however, it is not easy due
to the given heterogeneity of autism and the lack of specific biomarkers.
BTBR is one of the inbred mouse strains, which exhibits three core behavioral
characteristics

of

human

autism

clinical

symptoms.

These

behavioral

and

neuroanatomical characteristics have been extensively studied (Amodeo et al., 2012;
Blanchard et al., 2012; Meyza et al., 2013; Rutz et al., 2012; Sforazzini et al., 2014).
Although the mechanism underlying the behavioral deficits still need to be elucidated,
this particular mouse strain may be suitable for developing more specific biomarkers
and therapies. In this context, we examined plasma sulfate levels and cortical excitatory
amino acid transporter 3 (EAAT3) expression in BTBR mice compared to C57 mice. In
chapter 2, we reported a reduction in plasma sulfate levels in BTBR mice compared to
`
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C57 mice. The deficiency of sulfate and/or dysfunctional sulfate physiology has been
associated with autism in certain populations (Alberti et al., 1999; Bowling et al., 2013;
Geier et al., 2009). Because sulfate availability is important for detoxification of
xenobiotics during pediatric years, reduced sulfation may be a risk factor for autism by
making individuals more prone to xenobiotics induced toxicity (Schultz et al., 2016). The
idea of synergistic interactions between genetics and environmental factors is now
widely accepted; therefore, these features are particularly important in testing various
environmental factors that are implicated in the underlying cause of autism.
Another important finding in chapter 2 is that the BTBR strain had significantly
lower cortical EAAT3 levels. EAAT3, plays an important role in maintaining intracellular
cysteine levels in neurons (Watts et al., 2014). Neurons utilize cysteine to produce
glutathione (GSH) to combat oxidants and/or toxins. In fact, GSH is an essential
antioxidant in cells and plays a pivotal role in maintaining redox homeostasis (Schmidt
et al., 2012), and a dysfunctional GSH system has been implicated in autism (Dukhande
et al., 2009; Gu et al., 2013). Since intracellular transport of cysteine in neurons is
required to synthesize GSH (Watts et al., 2014), the reduced cortical EAAT3 levels may
affect overall redox homeostasis in the brain. Therefore, our finding of reduced cortical
EAAT3 levels is important and the BTBR strain may be a useful animal model to study
oxidative stress, GSH system dysfunction, the role of EAAT3 and cysteine often linked
to abnormal behaviors relevant to autism.
The overall results from chapter 2 provide evidence of both reduced neuronal
expression of EAAT3 and plasma sulfate levels in the BTBR mouse strain. In addition,
we observed reduced brain mRNA expression levels of Gclm and Gsr, and an increase

`
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in GSSG in plasma. While we found no differences in GSH levels and the ration of
GSH/GSSG in the plasma and the brain under basal conditions, taken all together our
findings suggest BTBR mice have increased vulnerability to oxidative stress due to the
diminished detoxification capacity.
Furthermore, there has been an increase in the number of human associated
studies linking early APAP exposure and autism as well as other neurobehavioral
disorders (Andrade, 2016; Carter et al., 2016; Schultz et al., 2016; Schultz et al., 2008;
Seneff et al., 2012; Shaw, 2013). Also, studies suggest that prenatal exposure to APAP
through maternal drug intake may cause abnormal behaviors in children, as well as
increasing prevalence in idiopathic autism (Andrade, 2016; Avella-Garcia et al., 2016;
Becker et al., 2010; Liew et al., 2016; Liew et al., 2014; Thompson et al., 2014). Even
though there is a growing interest in the possible link between early APAP exposure
and autism from both scientific/non-scientific communities, more research is needed to
determine if there is a causal relationship.
To investigate the effects of APAP on brain development, neonatal mice received
100 mg/kg APAP for 7 days and were subjected to behavioral tests at 3 month old age.
Contrary to what we hypothesized, overall behavior did not show differences between
vehicle and 100 mg/kg APAP. We think this contradictory is due to the dose and
duration of APAP administration. Based on what we observed, we believe increasing
the dose to 150 mg/kg and/or increasing treatment duration may alter behavioral
phenotypes (later explored in chapter 4). Beside the results from the behavioral tests,
we observed increased expression levels of EAAT3 in the frontal cortex and the
hippocampus. Perhaps, the elevated EAAT3 level is a compensatory action in response

`
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to APAP administration; however, more thorough investigation is needed to uncover the
role of EAAT3 in autism pathophysiology as well as neurodevelopment. Additionally,
although we did not find alterations in behavioral phenotypes due to early APAP
exposure at therapeutic doses, we were able to validate the behavioral characteristics
of the BTBR strain compared to C57 showing that BTBR mice tend to show increased
repetitive behaviors, less anxiety and decreased associative memory function.
In chapter 4, to investigate whether the BTBR strain responds differently to
xenobiotics compared to the C57 strain, we tested several doses of acetaminophen
(APAP) in neonatal mice. APAP is the most popular over-the-counter fever reducer and
pain killer. It is considered safe at therapeutic doses, but the safety of this drug has not
been fully investigated in the pediatric population. While human clinical doses are
calculated based on body weights in the pediatric population, more thorough
investigations are required since children detoxify and eliminate APAP via a different
mechanism than adults (Miller et al., 1976). APAP is metabolized in the liver and
converted to toxic metabolites. Then these toxic metabolites are eliminated via sulfation
and glucuronidation (Ganetsky et al., 2013). In the pediatric population, sulfation is the
major route of detoxification of APAP, thus dysfunctional sulfation may lead to
accumulation of toxic metabolites (Leonis et al., 2013; Miller et al., 1976).
In this chapter, we initially tested 3 doses of APAP (100, 200, and 300 mg/kg) in
neonatal mice via intraperitoneal (I.P.) injection for 7 days. The therapeutic dose (100
mg/kg) did not induced mortality, but 200 mg/kg and 300 mg/kg doses induced high
mortality rate. Therefore, we proceeded with the therapeutic dose, which did not show
toxicity and did not alter GSH levels. Later we evaluated a supratherapeutic dose (150
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mg/kg), which showed changes in GSH related enzyme activities and increased
oxidative stress markers in the brain homogenates. This finding is very important since
this dose is considered to be safe and therapeutic. It has been suggested that repeated
dosing within a short time (< 4 hr) and chronic use of APAP, even at the therapeutic
dose, may cause liver toxicity (Heubi et al., 1998). These observations should be used
to educate the public on the importance of proper APAP doses used in the pediatric
population.
We suggest that the findings from this study are sufficient to urge the public in
the use of APAP for pediatric population. Overall, this study suggests that 1) BTBR
strain might be suitable as a mouse model to investigate the potential contribution of
early exposure to various environmental insults when sulfation is primarily used for
detoxification, 2) sub-chronic administration of APAP at therapeutic dose during
neonatal period did not alter behavioral phenotypes, but it may alter antioxidant capacity
in the brain, and 3) APAP may alter normal brain development at the supratherapeutic
dose by changing important enzymes involved in antioxidant activity and detoxification.
Our study has laid the foundation for future prospective research designed to
better understand the APAP and autism association in humans. First, based on our
results from the supratherapeutic dose (150 mg/kg) in chapter 4, future studies should
include the supratherapeutic dose to confirm alterations in behavioral phenotypes.
APAP100 groups did not show changes in behavioral phenotypes in C57 nor did it
worsen the autistic behaviors in BTBR mice in chapter 3. The 150 mg/kg of APAP dose
however, may affect animal behaviors since we observed elevated GPx activity and
elevated HNE adduct levels. Interestingly, the 150 mg/kg dose still falls within the
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therapeutic range, and it would be important to test the supratherapeutic doses in
relation to neurodevelopmental changes. Furthermore, the duration of APAP
administration could be adjusted to be longer and/or repetitive. In our study, we used
daily I.P. injection for 7 days. Based on the observations made in humans, it is
implicated that chronic administration and/also repeated dosing may increase side
effects of APAP (Heard et al., 2014; Leonis et al., 2013).
In the future, measuring plasma and brain levels of APAP and its metabolites will
be important to ensure there is a production of the toxic metabolites. These metabolites
are thought to cytotoxic (Hogestatt et al., 2005; Kalinec et al., 2014; Nassini et al., 2010;
Schultz et al., 2012). This will be helpful to establish therapeutic and toxic doses of
APAP in mice, thus enabling more efficient research. Second, measurements of GSH
and GSSG appear to be largely non-significant in our data, therefore more sensitive
methodologies using different types of derivatizations and more sensitive detection
could assist in more precise and accurate analysis. Lastly, we could develop a battery
of behavioral tests to further assess memory and cognitive functions in BTBR mice as
we saw decreases in associative memory function in BTBR mice in chapter 3. Because
BTBR mice have reduced hippocampal commissure as one of the anatomical hallmarks
(Mercier et al., 2012), and we found reduce hippocampal EAAT3 expression (chapter 3),
it will be important for future research to investigate if EAAT3 is associated with memory
and cognitive functions.
Taken all together, we suggest that our study showed that APAP may have the
potential to have an effect on normal brain development. As addressed above, the
overall impact of APAP is dependent on its doses, duration and repeated
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administrations. Addressing these variables and their effect on autism may be critical to
aid human translational research. Nonetheless, the association between APAP and
autism is still controversial, and more investigations are essential to aid in the safety of
APAP administration in the pediatric population.
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